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Summary 
 
In the cell, the genetic information encoded in the DNA is transcribed to RNA. 
All RNAs that are transcribed in the cell are initially produced as precursor RNAs, 
which have to undergo various steps of processing to obtain their mature form. The 
maturation and processing for all RNA classes requires the activity of multiple RNA 
binding proteins (RBPs). An important family of RBPs that is involved in RNA 
maturation and processing is the SR-protein family. SR proteins are important for the 
regulation of a multitude of processes that include: splicing, transcription, export, 
RNA stabilization, translation and ncRNA processing. As of yet, there have been no 
comprehensive studies that describe how SR proteins dynamically regulate the 
maturation of RNAs. 
The results presented in this thesis provide new insights into the function and 
activity of SR proteins during RNA maturation. My experiments greatly expand the 
knowledge surrounding the action of RNA-binding proteins in vivo and in different 
cell compartments. 
To study the action of two different SR proteins in different cell 
compartments, I developed a new technique that combines cell fractionation and 
iCLIP, which I named FRACKING. For the first time, this method allowed me to 
collect information regarding the subcellular location where the RNA-protein 
interactions are taking place, giving a dynamic picture of the in vivo binding of SR 
proteins and of RNA binding proteins (RBP) in general.  
By using FRACKING on two heavily shuttling SR proteins, SRSF3 and 
SRSF7, I showed that both SR proteins are very dynamic in their binding behavior 
with RNAs. My research showed that both SRSF3 and SRSF7 strongly associate with 
RNAs during transcription (co-transcriptionally) and that they often remain bound to 
these transcripts until they are exported to the cytoplasm. The functions of SRSF3 and 
SRSF7 are closely related to their binding location on the target RNAs. I identified a 
subset of highly conserved introns that associated with SR proteins and are retained in 
their transcripts. These intron-retaining isoforms, contrary to textbook knowledge, are 
exported to the cytoplasm. 
I showed, for the first time, that SRSF3 and SRSF7 strongly interact with 
snoRNAs in the chromatin, and that this snoRNA-SR-protein binding behavior is 
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distinct between SRSF3 and SRSF7. SRSF3 binds to the mature snoRNA sequence, 
and also to the surrounding intronic sequences, pointing towards a possible activity in 
guiding snoRNA maturation. Whereas SRSF7 associates to mature snoRNA 
sequences. 
Taken together, my study identified a dynamic pool of interactions for two SR 
proteins, in different cell compartments and discovered new activities for the two SR 
proteins. Importantly, this study challenges textbook knowledge on splicing and 
export of mRNAs by identifying a subset of transcripts that can be exported even 
when they retain introns.  
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1 Introduction 
 
During gene expression, the genetic information encoded in the DNA is 
transcribed to RNA. These RNAs can either be pre-mRNAs or pre-non coding RNAs 
(pre-ncRNAs), depending on their capability to encode proteins or not. Importantly, 
all RNAs that are produced undergo, at some point in their life, modifications or 
maturation processes, to produce the mature form of such RNA. The maturation steps 
during processing are different for each RNA class. For example, pre-mRNAs need to 
be capped and polyadenylated, to ensure the stability of the transcript.  
Many eukaryotic mRNAs contain both coding regions (exons) and non-coding 
regions (introns). Through maturation, introns have to be removed from the pre-
mRNA to produce mRNA. The process that leads to the removal of introns is defined 
as splicing. The splicing of pre-mRNAs is usually constitutive, meaning that all exons 
are joined in the consecutive order where they are found in the transcript, after the 
removal of the introns. Any other case (i.e. exon skipping, intron retention or 
alternative splicing sites) is defined as alternative splicing. As for pre-mRNAs, all 
ncRNA classes have their own maturation pathways and processes. 
Maturation/Processing of both coding and non-coding RNAs requires the activity of 
multiple RNA binding proteins (RBPs). Most of these processing steps take place 
while the RNA is still being transcribed (co-transcriptionally) [1], but information 
regarding co-transcriptional activity of RBPs is still scarce. 
 
1.1 RNA binding proteins and the importance of forming RNPs in 
the cell 
 
Both ncRNAs and mRNA are rarely if at all, found “alone” in the cell. In fact, 
most RNA classes and certainly all mRNAs are bound by RBPs, often while they are 
still being transcribed, thus forming so called ribonucleoproteins (RNPs). This 
process is fundamental for stabilization and maturation of RNAs. RBPs guide and 
often catalyze important steps in the maturation and processing of mRNAs, as for 
example: transcription, 5’ capping, polyadenylation, export and RNA degradation 
(Figure 1.1) [2].  
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Figure 1.1: Schematic of various functions of RNA binding proteins in the cell. 
RNA binding proteins (RBPs) are involved in all processes important for RNA maturation and gene 
expression. RBPs bind to RNAs co-transcriptionally, forming mRNPs. Figure modified from [2]. 
 
RNPs contain different proteins depending, not only on the RNA itself, but 
also on the stage of maturation. The composition of these RNPs guides the fate of 
RNAs, defining whether they will be exported or degraded. The large diversity in 
activity of RBPs is partially due to the number of RNA binding domains (RBDs) 
present in the cell. More than 40 RBDs have been identified to this day [3]. The great 
capability shown by RBPs to bind different targets and different motifs is also linked 
to their modularity. Most RBPs are composed of multiple, often different RBDs, 
which help to recognize different targets and expand their repertoire of functions [4]. 
Furthermore, the modularity of RBPs allows them to promote or repress enzymatic 
activity, sometimes even of catalytic domains in the same protein, and to regulate 
such activity with binding specific RNA motifs or structures (as shown for the activity 
7meG
7meG AAAAAA
pre-mRNA splicing
Capping
Polyadenylation
 
mRNA
export
Nucleus
7meG AAAAAA
Translation
Transcription
Cytoplasm
7meG AAAAAA
mRNP
Spliceosome RNA binding proteins
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 Ribosome RNA po lymerase
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of Dicer in the maturation of miRNAs [5]). In recent years many experimental 
strategies have been developed to better define RBP targets, motifs, and functions. 
Some of these methods are discussed in more detail in chapter 1.5.  
More than 600 RBPs are annotated in the mammalian genome and recent 
experiments suggested that there are still new RBPs to be identified in the genome [6, 
7]. Many RBPs bind pre-mRNAs while they are still being transcribed by RNA 
Polymerase II (RNA Pol II) (i.e. co-transcriptionally) (Figure 1.1). This co-
transcriptional binding is a fundamental feature in pre-mRNA maturation; in fact, 
most key maturation processes, such as splicing, take place co-transcriptionally [1]. 
Pre-mRNAs are packaged into heterogeneous nuclear ribonucleoprotein particles 
(hnRNPs) [8]. These hnRNPs include a great number of intronic RBPs. Once the 
mRNAs are close to maturation, they are re-packaged in RNPs with a very different 
composition from the initial hnRNP complexes.  
The proper formation and composition of hnRNPs allows for proper 
maturation of pre-mRNAs. Nevertheless, a subset of proteins can bind RNA co-
transcriptionally and stay bound to this RNA until its translation. The exon junction 
complex (EJC) is one example. The EJC is fully assembled near the exon-exon 
junction, after splicing and in most cases, travels with the mRNAs to the cytoplasm 
[9, 10].  
A further example of RBPs that can bind co-transcriptionally and travel with 
their target RNAs are the splicing factors known as SR proteins. These proteins are 
not only of great importance for pre-mRNA splicing, but also in the export of such 
RNAs. Some members of the SR-protein family, in their hypophosphorylated state, 
can recruit the nuclear export factor 1 (NXF1) to bind RNAs, leading to the export of 
mRNA to the cytoplasm [11-13]. Furthermore, it has been shown that SR proteins are 
present at the site of transcription [14, 15], and that some of the proteins in this family 
can efficiently shuttle to the cytoplasm [14, 16].  
Overall, the action of RBPs and the formation of RNPs is a dynamic process 
that stimulates and guides many processes through the life of the target RNA. To date, 
however, most genome-wide techniques are not suited to take this into account and 
fail to report on the dynamics of RBP functions. So far, studies have only shown static 
pictures of RNPs in the whole cell.  Further insight into the dynamic aspect of RBP-
binding to RNAs is necessary to understand RNP formation and to fully characterize 
RNP functions. 
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1.2 SR proteins as multifunctional regulators of RNA  
 
The serine-arginine rich splicing factors (SR proteins) are a highly conserved 
family of RNA binding proteins essential for splicing and cell survival. Historically 
the canonical SR proteins were defined, in humans, as proteins containing a C-
terminal domain, composed of serine-arginine repeats, which are recognized by the 
monoclonal antibody mAb104 [17]. These proteins were shown to be able to activate 
splicing in vitro in S100 splicing deficient cell extracts [18]. These approaches 
identified the seven, so called “canonical” SR proteins, named numerically from 
SRSF1 to SRSF7 (Figure 1.2). 
 
 
Figure 1.2: Schematic representation of the whole SR-protein family. 
All SR proteins in the family contain one or two RNA recognition motif (RRM1 and RRM2) at their 
N-terminal end, followed by an RS domain of different length, for each SR-protein. SRSF7 contains a 
Zinc finger domain, which can regulates SRSF7 binding specificity. 
 
 
Recently, the definition of SR proteins was formalized, describing proteins 
that contain one or two RNA recognition motifs (RRMs) domains followed by an RS-
domain with at least 50 amino acids and more than 40% RS content, formed mainly 
by RS and SR repeats [19]. In this way, the family was extended to include twelve 
proteins (Figure 1.2). Additionally, in the genome there are a number of SR-like 
RRM 1 RRM 2 RS
RRM 1 RRM 2 RS
RRM 1 RS
RRM 1 RS
RRM 1 RRM 2 RS
RRM 1 RRM 2 RS
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proteins that do not fully fit the mentioned parameters, but still resemble the twelve 
SR proteins, both in structure and function.  
All SR proteins contain at least one, and in some cases two RRMs (Figure 
1.2). These are important for SR-protein interactions with RNA and they define the 
binding specificity of the protein. The RS domain is mostly implicated in protein-
protein interactions and can be post-translationally modified by phosphorylation [20]. 
The phosphorylation is known to modulate both the function and localization of SR 
proteins [12]. The knowledge about differential functions of the SR-protein domains 
has been greatly improved by recent studies. For example, some reports showed that 
the RS-domain contacts RNA at the branch point on the 5’ splicing site of some 
introns [21].  
Figure 1.3: Schematic of SR proteins activity in maturation, stability and export of RNAs.
SR proteins are known to be involved in most steps of RNA maturation, and are necessary for proper 
RNA maturation. Figure modified from [2]. 
Initially SR proteins were thought to preferentially bind exons on exonic 
splicing enhancers (ESE) thereby, aiding in the inclusion of such exons [22]. Studies 
using model genes showed that SR proteins could also bind intronic sequences, 
identifying possible intronic splicing enhancer sites (ISE) [23]. Furthermore, recent
genome-wide studies, using techniques such as ultraviolet (UV) crosslinking 
AAAAAA
A
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60S
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immunoprecipitation (CLIP-seq), have shown that SR proteins have a great number of 
binding sites in intronic regions [24-27].  
SR proteins do not only bind coding RNAs, but also to many different classes 
of ncRNAs [24, 25, 27], including small nucleolar RNAs (snoRNAs), long non-
coding RNAs (lncRNAs), and microRNAs. 
The function of a SR-protein begins when it binds to its target RNA in the 
nucleus. Many, but not all of the actions mediated by a SR protein occur in the 
nucleus. SR proteins are involved in a multitude of processes, including: splicing, 
transcription, RNA export, RNA stability, translation and ncRNA processing (Figure 
1.3). Their regulation of these processes will be described as follows: 
 
Constitutive splicing regulation: Historically SR proteins were defined as splicing 
factors due to their ability to complement splicing-deficient cellular extracts.  Our 
understanding of their role in splicing has greatly increased. Thus far, we know that 
they are not part of the core spliceosome complex, yet SR proteins are essential 
during spliceosome recruitment and activation. Both in vivo and in vitro studies have 
shown that SR proteins can bind exons and help strengthen weak splicing sites in 
constitutive exons [26, 28, 29]. They help in defining the exon-intron boundary and 
with the subsequent recruitment of spliceosome subunits such as the snRNP U1 and 
the U2 auxiliary protein (U2AF), which are recruited at the 5’ and 3’ splicing sites, 
respectively [20, 30, 31]. The activity of SR proteins in splicing has been shown to 
occur through a positive enhancement of splicing, but SR proteins can also play a role 
in repressing splicing. In fact, depletion of single SR proteins demonstrated up-
regulation of a great number of exon skipping events [26]; furthermore, 
dephosphorylated SRSF10 has shown to be able to act as a splicing repressor [32].  
 
Alternative splicing regulation: SR proteins are not only involved in canonical 
splicing events but are also important for alternative splicing. It is still unclear how 
singular SR proteins contribute to cell or tissue specific alternative splicing. In fact, 
SR proteins are ubiquitously expressed in various cells and present only a few cell-
type specific differences [33]. Nevertheless, even small, combinatorial differences in 
protein levels can be enough to mediate great changes in alternative splicing patterns 
[34].   
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Through the tethering of SR proteins to exons, it has been possible to show 
that binding to an internal cassette exon enhances its inclusion and, instead binding to 
the flanking exons enhances skipping of the internal exon [35]. Nevertheless, it has 
been challenging to obtain genome-wide data on alternative splicing regulation 
operated upon by SR proteins. SR proteins are essential for cell viability and cannot 
be fully depleted from most cell lines. Partial depletion of single SR proteins is not 
sufficient to obtain the deregulation of their targets, which is due to the fact that SR 
proteins have partially redundant targets and can compensate for each other. This adds 
another layer of complexity to the regulation of alternative and canonical splicing by 
SR proteins. 
 
Transcription regulation: Splicing is known to take place mainly co-transcriptionally 
with many indications that transcription and splicing are closely interconnected and 
that transcription can influence splicing [1, 36-38]. We know that SR proteins are 
present at the site of transcription and that they are co-transcriptionally recruited to 
chromatin [14, 15]. Furthermore, RNA Pol II was shown to influence the recruitment 
of SR proteins to newly transcribed RNAs [39]. At the same time, SR proteins can 
feed back on transcription; in fact, SRSF2 can enhance transcription elongation 
through interactions with the C-terminal domain of the largest subunit of RNA Pol II 
and with the positive transcription factor b (P-TEFb) [40]. Furthermore, SRSF1 and 
SRSF2 have recently been shown to help release paused RNA Pol II near the 
transcription start site (promoter proximal pausing) [25]. It has also been shown that, 
during mitosis, SRSF1 and SRSF3 can interact with chromatin through binding of 
histone H3 tails [41]. This shows that SR proteins are key regulators in the interplay 
between co-transcriptional splicing and transcription. 
 
Export regulation: The ability shown by most SR proteins to continuously shuttle 
between the nucleus and cytoplasm is key for their activity as export adapters [11, 12, 
16]. SR proteins can bind pre-mRNA and often maintain this interaction and mediate 
RNA export to the cytoplasm. To shuttle to the cytoplasm, mRNP complexes need to 
pass through the nuclear pore complex (NPC). For this to happen, the mRNPs need to 
contain the nuclear export factor 1 (NXF1), which mediates the export of most 
mRNAs. Interestingly, NXF1 has only weak RNA binding capabilities and requires 
adapter proteins to bind RNAs specifically; in most cases, these adapter proteins are 
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the SR proteins. It was shown that some SR proteins can directly interact with NXF1 
and that they are necessary for the export of some mRNAs [11]. mRNPs contain both 
SR proteins and NXF1 can interact with the NPC through NXF1 and mediate their 
export to the cytoplasm where SR proteins can then influence stability and translation 
of the bound mRNA. 
 
Translation regulation: SRSF1 can interact with active ribosomes and it can enhance 
translation of its target mRNA [42]. Similar to differential effects in splicing 
regulation, SR proteins can also negatively affect translation.  In fact, SRSF3 has been 
shown to down-regulate translation by binding the 5’UTR of its target mRNA [43]. 
 
Stability regulation: Any RNA produced in the cell is subject to quality control. One 
of the main control mechanisms is called nonsense-mediated decay (NMD) (a 
complete explanation of NMD and RNA surveillance can be found in chapter 1.3). 
NMD is triggered by the presence of a premature stop codon (PTC) on the mRNA, 
leading to the degradation of such mRNAs in the cytoplasm. Interestingly, through 
alternative splicing of ultra-conserved exons or introns, all SR proteins can produce 
PTC containing isoforms that are then recognized and degraded by NMD [44]. 
Furthermore, it has been shown that SR proteins can regulate alternative splicing of 
such isoforms and thus can regulate the stability of their own transcript in a 
concentration dependent manner [24]. This indicates the presence of an important 
negative feedback loop through which SR proteins can tightly regulate their own 
levels. In fact, misregulation of SR proteins can lead to cancer [45]. The regulation 
operated by SR proteins on other stability mechanisms is still not fully understood 
[46].  
 
ncRNAs and SR proteins: SR proteins have the ability to interact with different classes 
of RNAs, including both coding and ncRNAs. Studies using overexpression or 
imaging techniques have shown that a subset of SR proteins strongly interacts with 
and co-localizes to the Metastasis-Associated Lung carcinoma Transcript 1 
(MALAT1). MALAT1 is one of the better-studied lncRNAs, and it is one of the main 
components of nuclear speckles [47]. Interestingly, both SR proteins and MALAT1 are 
localized to nuclear speckles even though MALAT1 does not seem to be necessary for 
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speckle formation in mice [48]. The combination of MALAT1 and SR proteins is 
sufficient to nucleate such speckles [49].  
MALAT1 plays an important role in the regulation of the re-phosphorylation of 
SR proteins [47]. SR-protein phosphorylation status is fundamental for their 
subsequent localization and function in splicing. In fact, only phosphorylated SR 
proteins can mediate spliceosome recruitment. Following splicing, the SR proteins are 
dephosphorylated. Only un-phosphorylated SR proteins can interact with NXF1 and 
mediate RNA export, thus showing the importance of the interaction between SR 
proteins and MALAT1.  
It has been shown that SR proteins can bind miRNAs [24], specifically SRSF1 
can regulate the maturation of miR-7 by binding to it and promoting its processing 
which is carried out by Drosha [50]. It seems very likely that this might not be the 
only example where a SR-protein can regulate miRNA biogenesis. Further studies 
will be necessary to fully understand and characterize such SR-protein activity. 
Finally, individual nucleotide resolution ultraviolet crosslinking and 
immunoprecipitation (iCLIP) analysis of SRSF3 and SRSF4 has shown that these SR 
proteins can associate with small nucleolar RNAs (snoRNAs) [24]. It has been 
proposed that such interactions might facilitate snoRNA biogenesis. Unfortunately, 
this hypothesis was never confirmed experimentally and further data would be needed 
to consider this possibility. 
 
In conclusion, we see how the multifunctionality of SR proteins renders them 
the handymen of the cell by being involved in most cellular processes. 
 
 
1.3 Regulation of RNA stability in the cell 
 
 
RNA degradation is a fundamental and highly regulated part of the cell life. 
Despite great differences in the complexity of specific degradation pathways, 
similarities between bacteria, archaea and eukaryotes exemplify the importance of 
RNA stability regulation and show that this regulation formed early in evolution [51]. 
There are two main players in RNA degradation. The first important players are the 
RNA-degrading enzymes, which can be subdivided into the endonucleases that cut 
RNA internally, and the exonucleases that can cut either from the 5’ end or 3’end of 
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the RNA. The second type of enzyme fundamental for many decay mechanisms are 
the helicases. These encompass ATP-dependent enzymes that can remodel the RNA, 
or aid in bringing complexes to sites of RNA interaction, or act as “place markers” in 
recruiting the degradation machinery to a specific RNA site [52, 53]. RNA 
degradation presents several differences depending on which class of RNA is being 
degraded, and what type of degradation is taking place: 
 
RNA Processing: all RNAs that are synthetized as larger precursor RNAs, need to 
undergo partial degradation, which is referred to as maturation. These RNAs are 
processed at their 3’ or 5’ end with nucleases. This degradation pathway is very 
important, both for the maturation of a subset of ncRNAs but also to avoid cluttering 
the cell with small, unused pieces of RNAs removed from functional RNAs (i.e. 
introns). 
 
mRNA and ncRNA turnover: the regulation of both ncRNA and mRNA levels is a 
fundamental step for all cells, which permits a continuous and tight regulation of gene 
expression and protein levels. 
 
Quality control: the cell continuously surveys RNAs to identify and degrade those 
that are defective. Between the different surveillance pathways there are two 
important mechanisms that recognize RNAs possessing a premature stop codon 
(PTC) in their sequence. Those mechanisms are: Nonsense mediated decay (NMD) 
and Nonsense mediated translation repression (NMTR) [54]. Among these 
mechanisms, the best characterized and most well known is NMD [55-57]. Even 
though it has not been fully described, NMTR is important due to the mere fact that it 
appears to target PTC containing, NMD-resistant mRNAs, without relying on the 
same machinery as NMD. This mechanism may act as a failsafe for NMD, possibly 
targeting a subset of NMD-resistant RNAs [54, 58]. 
 
1.3.1 The regulation of mRNA stability operated through NMD 
 
Since all the SR-protein transcript levels are regulated by NMD, I will here 
further discuss and summarize its action. Even though all surveillance mechanisms 
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differ greatly from one another, the actions of all surveillance mechanisms can be 
subdivided into three major steps: detection, tagging and destruction (Figure 1.4).  
The protein coding potential of an mRNA is likely to determine whether that 
RNA will be stable or not. In fact, NMD recognizes PTC-containing transcripts and 
the key proteins for NMD are UPF1, UPF2, UPF3a and UPF3b [55-58].  
NMD largely, if not exclusively, degrades newly synthesized mRNAs and the 
recognition of its targets is deeply interconnected with translation termination. NMD 
is actually triggered at the end of the first round of translation, also called the “pioneer 
round”. mRNAs that have not yet undergone translation are associated with the cap 
binding complex (CBC, composed of the heterodimer CBP20-CBP80) and, if derived 
from splicing, they will also be associated with the exon junction complex (EJC), 
which is deposited 20-24 nt upstream of exon-exon junctions [9, 59]. Both the CBC 
and EJC are important and often fundamental for efficient NMD activation.  
The first signal necessary for the activation of NMD comes from termination 
factors. If the termination factors (eukaryotic Release Factor 1 and eukaryotic Release 
Factor 3 complex) are assembled at a termination codon that precedes more than 50-
55 nt from an exon-exon junction, the ribosome is unable to remove the EJC. This 
signals to the cell that NMD needs to be initiated. In fact, the presence of an exon-
exon junction after a termination codon creates an aberrant situation for the cell. The 
main NMD factor is UPF1, which is an ATP-dependent helicase that initially interacts 
with CBP80 and the terminating ribosome on mRNAs. UPF1 interacts also with 
SMG1 (a serine/threonine kinase) and forms, in this way, the SURF complex (as 
shown in Figure 1.4, top panel). The second signal for NMD activation is orchestrated 
by the EJC. In fact, the protein UPF2 is connected to the EJC by either UPF3a or 
UPF3b [10].  
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Figure 1.4: Schematic of RNA quality control operated by NMD.  
NMD quality control can be separated in three steps: detection, tagging and degradation. Here we have 
a schematic of the NMD process from the time that an mRNA containing a premature stop codon is 
identified until its degradation. Figure modified from [55]. 
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When the SURF complex is formed at a termination codon preceding more 
than 50 nt from an EJC, the mRNA is signaled as a target for NMD. Once a target has 
been detected, part of the SURF complex associates with UPF2-UPF3a (or UPF3b), 
the latter of which are part of the EJC, thereby forming the decay-inducing complex 
(DECID). It is still not fully understood how SURF and EJC, when sitting at such 
great distances from one another, can come together. In a rate-limiting step, SMG1 
kinetic activity is stimulated leading to the phosphorylation of two residues: one at the 
N- and the other at the C-terminal domain of UPF1 [60]. The phosphorylation of 
UPF1 triggers translation repression, which is fundamental to occur before the mRNP 
can be degraded. At this point the mRNAs that have phosphorylated UPF1 are tagged 
for destruction, which can take place through two different parallel pathways, as 
orchestrated by SMG6 and SMG5.  
Phosphorylated-UPF1 recruits SMG6, which displaces UPF3a or UPF3b from 
the EJC [61]. At this point SMG6 cleaves the target mRNA, generating a 5’ cleavage 
product that contains the PTC, and a 3’ cleavage product that is associated to EJC and 
NMD components. The 5’ product is then likely degraded from 3’ to 5’ via the 
exosome. The 3’ product is then freed from the bound proteins by the helicase activity 
of UPF1. This facilitates 5’-to-3’ exonuclease degradation. At the same time, UPF1 
recruits SMG5 which, in turn, can recruit other proteins that stimulate the decapping 
and deadenylation of the target mRNA, leading to degradation of the RNA from both 
ends [62]. In this way, NMD can degrade mRNAs through two different but similar 
mechanisms. When NMD has completed, its components are then recycled to be used 
for successive rounds of NMD.  
 
1.4 Small nucleolar RNAs (snoRNAs) 
 
snoRNAs are an evolutionally conserved class of ncRNAs. They were initially 
called 'small nucleolar RNAs' due to the strong localization to the nucleolus of the 
first members identified in this class. To date, most known snoRNAs function in the 
modification and maturation of ribosomal RNAs (rRNA) [63].  
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Figure 1.5 Genomic locations of snoRNAs and their secondary structures. 
A) Representation of different possible locations of snoRNA genes in the genome. Big boxes represent 
exons; smaller boxes represent snoRNA genes. Figure modified from [64]. B) A schematic 
representation of the secondary structure of C/D box snoRNAs (left) and H/ACA box snoRNAs (right). 
Red lines represent target RNA that is recognized by snoRNAs. Blue boxes, in right panel, represent C, 
C’, D and D’ boxes. Yellow boxes, in left panel, represent H and ACA boxes. Figure modified from 
[65]. 
 
In the cell, snoRNA genes exhibit a variable organizational pattern (Figure 
1.5A). snoRNAs can be initially transcribed from independent RNA Pol II genes or 
they can also arise from introns excised from other transcripts with or without coding 
potential. Finally, snoRNAs can originate, from polycistronic transcripts (Figure 
1.5A). It is important to note that many snoRNAs present different functions and do 
not necessarily localize to the nucleolus [66].  
snoRNAs are divided into two different families: the C/D and the H/ACA 
RNAs, depending on their conserved nucleotide sequence motifs and structure (Figure 
1.5B). These two families of snoRNAs are known to guide different processes of 
RNA modification; box C/D snoRNAs are known to guide 2’-O-ribose methylation, 
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whereas box H/ACA snoRNAs guide pseudouridylation (i.e. the conversion of an 
uridine nucleotide to a pseudo-uridine). 
Each family of snoRNAs requires its own set of specific effector proteins to 
form functional snoRNPs. Protein association is initiated co-transcriptionally and 
appears to be required to stabilize newly transcribed snoRNAs to prevent their 
degradation. How many and which accessory proteins guide snoRNAs maturation to 
generate functional snoRNPs remains unknown [67, 68]. The number and identity of 
many of the proteins acting as chaperones and recruiting factors for the formation of 
snoRNPs, has yet to be determined as well.  
snoRNAs can originate from different transcripts, with the majority of 
snoRNAs being of intronic origin (Figure 1.5A). During the course of their 
maturation, snoRNAs transit through the Cajal body, a complex nuclear body 
enriched in factors involved in RNA modification and in the assembly of RNA-
protein complexes. There, the snoRNAs are modified to be functionally active. Most 
snoRNAs function as RNA guides for the modification of specific target RNAs.  The 
biochemical activity is provided by the protein components within the snoRNP 
complexes.  
The C/D box snoRNAs are so named according the box C motif (RUGAUGA, 
where R can be A or G), usually located near the 5’end, whereas the D box motif 
(CUGA) is located near the 3’end. The secondary structure of mature snoRNAs 
brings these two motifs together by nucleotide base pairing of the 5’ and 3’ ends 
(Figure 1.5B). Many C/D snoRNAs also contain one other set of C and D boxes, 
which are divergent but still functional [69], called C’ and D’. C/D snoRNAs bind to 
their substrate with their guide element, which can range between 10-20 nt in length 
and is positioned upstream of box D (and/or D’). Typically these snoRNAs guide the 
methylation of their targets at a site located ~5 nt from the D box (Figure 1.5B). The 
enzyme that catalyzes this methylation is Fibrillarin. Three additional proteins are 
required to form the functional snoRNPs: Nop56, Nop58 and the 15.5 kDa protein. 
The H/ACA snoRNAs differ greatly from the C/D snoRNAs, as they possess 
different box motifs and different secondary structures. H/ACA snoRNAs can 
typically form one hairpin loop, but can also form even two or, more rarely, up to 
three consecutive hairpin loops. In H/ACA snoRNAs with two or more stem-loops, 
these regions are separated by the conserved motif, known as the H box sequence 
(ANANNA). Another conserved motif is the ACA box, which is usually located 3 nt 
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upstream of the 3’ end. One of the two hairpins, and sometimes both hairpins, 
contains an internal loop of variable length with antisense elements that recognize the 
target RNA and form the pseudouridylation pocket. The pseudouridylation site is 
roughly 15 nt from the H or ACA box. Importantly, the enzyme carrying out the 
catalytic reaction for pseudouridylation is known as Dyskerin. Three other proteins, 
GAR1, NHP2, and NOP10, are fundamental for the function of these snoRNAs. 
 
1.5 RNA-protein interaction identification in a genome-wide context 
 
 
RBPs are necessary for the processing and maturation of all RNAs, as 
discussed in section 1.1. In order to further address the activity and identify targets of 
RNA binding proteins, one needs experiments that are able to tackle such questions 
with a genome-wide and specific approach. Thus far, different techniques have been 
described that help identify RNP targets.  
The first approach combined RBP immunoprecipitation with microarray 
analysis (RIP-chip) to identify RNA targets for a specific RBP [70], but this technique 
presented some limitations [71]. RIP-chip experiments are limited to only very stable 
protein-RNA complexes. They are also lower in resolution, in that this technique 
cannot identify the precise site of binding on the target RNAs. Finally, RIP-chip is 
prone to detect non-specific RNA-protein interactions. To improve on these 
limitations and identify high resolution binding sites, a method known as ultraviolet 
(UV) crosslinking immunoprecipitation (CLIP) was developed [72, 73]. This method 
combines UV crosslinking, which can create a covalent bond between proteins and 
RNAs that are directly interacting, with stringent immunoprecipitation (IP) and 
purification steps. 
Since most RBPs bind short, degenerate RNA motifs, it is insufficient to 
identify only the RNA targets of a RBP. It is fundamental to also locate the precise 
sites of binding of the RBP. The combination of the initial CLIP technique with next 
generation technique (CLIP-seq or HITS-CLIP) [74] allows researchers to have a 
precise, genome-wide technique for the identification of RBP targets. To advance as 
close as possible to a single nucleotide resolution of protein binding behavior, new 
modifications to these techniques were applied and in this way two techniques were 
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developed: photoactivatable ribonucleotide enhanced CLIP (PAR-CLIP) [75] and 
individual nucleotide resolution CLIP (iCLIP) [76]. 
iCLIP is probably the one technique that can provide a more natural landscape 
of RBP binding to RNAs. In fact this method does not employ the introduction of 
modified nucleotides or mutations to define the precise binding site of the RBP tested 
(for a detailed explanation of the iCLIP technique refer to Figure 1.6). iCLIP can 
identify specific protein binding sites and their targets, with high precision and 
resolution [76, 77]. Furthermore, from negative control experiments it has been 
shown that nonspecific reads are almost absent; these controls are done by using 
either knockout cell lines for the tested protein or by omitting the initial UV-step [24, 
77, 78]. 
The data produced by iCLIP requires specific and powerful bioinformatic 
analysis, to permit proper biological interpretation. The data needs to be mapped and 
then it needs to be clustered and normalized to gain the statistically significant 
binding sites [79]. From iCLIP data, one usually obtains a variable number of binding 
sites; these sites can be roughly divided into high and low occupancy sites depending 
on the strength of signal at those specific sites. Furthermore, the low occupancy sites 
usually, and unsurprisingly, outnumber the high occupancy sites, but these high 
occupancy sites appear as clusters of reads. The identification of such clusters is 
needed to calculate the significant enrichment of signal over local background signal, 
in the regions surrounding the same gene. 
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Figure 1.6: The iCLIP protocol schematic. 
In iCLIP, cells are treated with UV at a wavelength of 254 nm so that RNA-protein complexes are 
crosslinked and a covalent bond is formed between the RBPs and their target RNAs.  The crosslinked 
cells are then lysed and the RNA is partially digested to have shorter RNA-RBP complexes. Finally, 
the RBP of interest is immunoprecipitated using either a specific antibody (if available) or, tagged 
proteins can be immunoprecipitated using an antibody specific for the tag. In this step, stringent wash 
steps can be used as RBPs and RNAs are covalently bound. These wash steps allow for the removal of 
false positive interactions from the sample. Once the specific RBP-RNA complexes are selected, the 
L3 linker adapter is ligated to the 3’ end of the RNAs. The L3 linker is specifically used in next 
generation sequencing. The 5' end of the RNA is at this point dephosphorylated and then labeled by the 
addition of a radioactive nucleotide. In this way the RNA-protein complexes can be detected and 
separated by SDS-page. Next, the protein-RNA complexes at the appropriate molecular weight are cut 
from the membrane and the samples are treated with proteinase K so as to obtain free RNAs. A small 
peptide is left on the RNAs. This peptide is needed to stop reverse transcription (RT) at that site, 
defining the precise nucleotide at which the RBP was bound to its target. The RT primer contains in its 
sequence: a complementary region to the L3 linker, an upstream restriction site for BamH1, a second 
adapter (an other specific sequencing primer), and a barcode sequence that is used to detect and remove 
PCR duplicates from the deep-sequencing data. The single-strand-cDNAs are then separated on a TBE-
Urea gel. At this step, the ss-cDNAs are divided by their size into long (L), medium (M), and short (S) 
cDNAs; this size sorting step is needed to avoid size bias in the successive library preparation steps. 
The cDNAs are then circularized and cut with BamHI at the site in between the adapters. This produces 
linearized ss-cDNAs that have, from the 5’-end: a sequencing adapter, the barcode sequence, and the 
target sequence, which importantly start with the nucleotide representing the protein-binding site. At 
this point the cDNA are amplified by PCR using the sequencing primers. The L, M and S samples are 
pooled back together into a single sample in different amounts to account for the different intensity of 
the PCRs. The samples can then be submitted for high-throughput sequencing. 
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1.6 Subcellular Fractionation 
 
Eukaryotic cells are divided into cell compartments and diverse organelles, 
each with unique functions and protein populations. To fully understand protein 
composition and functions of the different compartments and/or organelles, 
researchers have developed and perfected many different types of cell fractionations 
[80]. Different subcellular fractionation protocols have been developed to isolate 
nuclei from cytoplasm, protocols that specifically isolate organelles such as 
mitochondria, or protocols that are able to isolate specific cell components. These 
subcellular fractionations always need to be tested and optimized depending on the 
cell line used [80].  
Initially it is necessary to decide how to disrupt the cells, using either 
chemicals and detergents to swell and burst the cells or a homogenizer that can use 
mechanical stress to break the cells and/or tissues. The fractionation and purification 
of a clean final product requires different steps of centrifugation and washes with 
different buffers and detergent concentrations. During centrifugation, cellular 
components are pelleted based on size, density, and sedimentation properties. As 
mentioned, numerous centrifugation steps with different centrifugal force can 
effectively fractionate the cells.  
Numerous protocols have an initial 5–10 min centrifugation step at ~1000g 
that pellets the nuclei, mitochondria, and sheets of plasma membrane [80]. The 
resulting supernatant is often referred to as the postnuclear/postmitochondrial 
supernatant. Subsequent centrifugation steps can then be used to isolate lysosomes, 
peroxisomes, endosomes, Golgi membranes, and other subcellular compartments. 
Furthermore, purification of the fraction of interest may, at times, be achieved by 
using additional rounds of centrifugation with continuous or discontinuous density 
gradients, as in the case of polysome fractionations. The medium used for the 
formation of gradients is usually sucrose. Sucrose gradients can be used with 
concentrations ranging from 2% to 70% allowing most subcellular components to be 
separated. To assess the purity of the selected fractions, the fractions are usually 
tested by their protein composition (using Western blots) or with enzymatic assays for 
particular organelles (e.g. Golgi). 
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1.6.1 Isolation of Nuclei 
 
The subcellular fractionation of nuclei from cytoplasm is often the first step in 
the study of subcellular localization of proteins, nuclear-cytoplasmic shuttling, 
nascent RNA isolation, and so on. Interestingly, methods to cleanly separate nuclei 
from cytoplasm have been used since the late 1940s [81, 82]. To this day, many 
methods to isolate cytoplasm, nuclei, and chromatin, have been developed and 
optimized, for many species and cell lines [1, 83]. Nevertheless, even though a 
fractionation method might be applicable to one cell line or tissue it might not yield 
the same clean results for different cell types or species [80], due to differences in 
cell/tissue structure and properties. Therefore, a fundamental step of every new 
fractionation involves the optimization and modification of the existing methods to 
best suit the case studied. 
As mentioned in the previous session, fractionation methods can vary 
dramatically, even when the final product involves obtaining the same organelle or 
subcellular compartment or structure. In the case of nuclear/cytoplasmic fractionation, 
we can distinguish between two methods. The first method involves detergent based 
fractionation, which uses particular concentrations of NP-40 or Triton X-100 to 
disrupt cells, and if needed, also disrupt the nucleus (i.e. in the case of chromatin 
preparations) [84]. The second method uses homogenization to break cells followed 
by high-speed centrifugation in specific sucrose gradients to separate the nuclei from 
the cytoplasm and/or unbroken cells [80]. Each of these methods has advantages and 
disadvantages. The detergent based method is rapid and allows isolation of total 
cytosolic and nuclear fractions, with little or no cross-contamination, and it requires 
no particular equipment. Unfortunately, this method affects protein-protein complex 
integrity and enzymatic activity, making it sub-optimal for enzymatic studies. The 
sucrose gradient method allows for a clean purification of nuclei, but it is a long 
procedure (more than 2h) and this can lead to a higher chance of protein degradation 
or translocation, leading to variability in the quality and quantity of the organelle 
yields. The quality of the samples, isolated with these methods, are usually tested 
using western blots and fraction-specific protein localization. Once the sample is 
confirmed to be clean, it can be used for subsequent experiments and analyses. 
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1.6.2 Isolation of Polysomes 
 
Ribosomes are complex macromolecules that are composed of two different 
subunits: large and small subunits. These ribonucleoprotein complexes are composed 
of up to 80 proteins and four RNAs, in eukaryotes. The two subunits of the ribosome 
interact with one another and with other proteins and RNA during protein synthesis. 
Importantly, eukaryotic cytoplasmic ribosomes have a sedimentation coefficient of 
80S, for the monosome, and 60S and 40S for the large and small subunit, respectively 
(Figure 1.7A). Isolating ribosomes has been of great importance in the past to study 
RNA translation and ribosome activity. There have been a number of protocols 
developed depending on specific species [85-87].  
 
 
Figure 1.7: Representation of sucrose gradient and polysome fractionation 
A) Schematic representation of sucrose gradient used to extract polysome fractions. With different 
concentrations of sucrose, single ribosomal subunits, monosomes and polysomes can be isolated. B) 
Profile of ribosomal subunit distribution for the polysome fractionation. Subsequent polysome fractions 
from the sucrose gradient are extracted and their absorbance is measured at 254 nm. Here are detected: 
the peak of the 40S small ribosome subunit, the peak of the 60S large ribosomal subunit, the 80S peak, 
representing the monosome, and several less pronounced peaks, representing the polyribosomes. 
 
 
The basic steps of purification are the same for most organisms. Initially, cells 
are gently disrupted, and then the heavy cell debris produced is removed with a low 
speed centrifugation step, followed by differential ultracentrifugtion to sediment on a 
sucrose gradient. The sucrose sedimentation step allows for the separation of the 
soluble debris with ribosomal subunits, the monosome and the polysomes. Polysomes 
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are the complexes formed by multiple ribosomes held together by their interaction 
with the RNA that they are translating (Figure 1.7A).  
The fractions extracted from these gradients are tested by calculating their 
absorbance profile at 254 nm (Figure 1.7B). The later fractions of the gradient, which 
are denser, contain the polysomes, still associated with RNAs that they were 
translating. In spite of being quite laborious and time consuming, this method 
produces clean ribosomal and polysomal fractions that can be further tested for 
protein or RNA presence/localization, by either western blot or reverse transcription 
combined with PCR. 
 
1.7 Aim of the thesis 
 
Many questions concerning the various activities of SR proteins in the maturation 
of different classes of RNAs remain unanswered. For example it is unclear how SR-
protein binding evolves through RNA maturation and what is the interplay of the co-
transcriptional activity of SR proteins.  
The overall aim of my thesis is to gather a more dynamic picture of SR-protein 
activities in the regulation of RNA maturation and stability in the cell. To achieve 
this, I developed a new technique called FRACKING, which combines cell 
fractionation and iCLIP. This new technique allowed me to gather high-resolution, 
transcriptome-wide data of the dynamic binding of two SR-protein family members, 
SRSF3 and SRSF7, which are representative of this class of RBPs. Due to the ability 
provided by FRACKING in revealing rare and important protein binding properties 
during the life of RNAs, I was prompted to ask the following specific questions: 
 
1. Are the SR proteins, SRSF7 and SRSF3, binding RNA co-transcriptionally? 
Can we observe changes in protein-RNA binding interactions in different 
subcellular fractions? 
The results provided by FRACKING allowed me to detect that, for 
most of their targets, SRSF3 and SRSF7 binding occurs co-
transcriptionally. Furthermore, this binding behavior changes through 
maturation of the RNAs. I identified how SR proteins accumulate in 
UTRs only in the cytoplasm. Meanwhile, intronic binding of SRSF7 
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and SRSF3 occurs almost exclusively in the chromatin and 
nucleoplasmic fractions.  
 
2. Can we identify novel activities for SR proteins during RNA-maturation? 
I identified a subset of transcripts that exhibited intron-retention and 
that were exported to the cytoplasm. These intron-retained transcripts 
showed high SR-protein binding behavior along their retained introns. 
Furthermore, approximately 78% of the identified introns were highly 
conserved in mammals, raising the possibility that SR proteins mediate 
the export of these isoforms to the cytoplasm. I successfully validated 
the presence of these isoforms in the cytoplasm and specifically 
verified their association with polysomes. However, I could not fully 
characterize whether these transcripts are stable in the cytoplasm and 
whether they can produce peptides. 
 
3. Can we identify novel functions of SR proteins that are specific for subcellular 
compartments? 
Here, I was able to show that both SRSF3 and SRSF7 associate with 
snoRNAs in the chromatin. Furthermore, this binding behavior varies 
greatly between the two SR proteins. SRSF7 binds almost exclusively 
to mature snoRNA sequences. Conversely, SRSF3 binds strongly also 
to the regions surrounding the mature snoRNA sequences. These 
findings indicate a differential regulation of snoRNAs by distinct SR 
proteins. 
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2 Results 
2.1. Expression levels of BAC transfected P19 cell lines 
To illustrate the dynamic RNA binding properties of SR proteins, I selected 
two specific SR proteins to test. The two SR proteins selected as the main focus of my 
study are SRSF7 and SRSF3, owing to their ability to strongly shuttle between the 
nucleus and the cytoplasm [14, 16], and for the fact that they are well characterized as 
mRNA export adapters [11, 12]. 
Figure 2.1: Characterization of SRSF3-GFP and SRSF7-GFP transfected P19 cell lines. 
A) Schematic representation of SRSF3 and SRSF7 domains and GFP tag position B) Western blot 
analysis of proteins extract from WT and SRSF3-GFP transfected P19 cell lines. The specific anti-
SRSF3 antibody, 7B4, was used to detect both endogenous and the GFP-tagged SRSF3. C) Western 
blot analysis of proteins extract from WT and transfected P19 cell lines for SRSF7. Specific anti-
SRSF7 antibody was here used to detect both endogenous and transfected proteins. 
To effectively study SRSF7 and SRSF3 in P19 cells, I used transgenic cell 
lines where either protein was tagged at its C-terminal region with a GFP tag, as 
presented in Figure 2.1A. These cell lines were previously produced and described in 
the lab [14, 24, 88]. These cell lines have a stably integrated supplementary copy of 
the specific SR-protein expressed under their own promoter. I used P19 cells, which 
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are embryonic carcinoma cell lines, derived from a mouse embryonic-
teratocarcinoma. P19 cells are pluripotent cells and can differentiate into the cell types 
of all three germ layers. For my study, I used undifferentiated cells stably transfected 
with a copy of either SRSF3 or SRSF7.  
To characterize the expression pattern of the tagged SR proteins in these cell 
lines, I prepared total protein extracts from WT and transfected cell lines for SRSF3-
GFP or SRSF7-GFP. I loaded the protein fractions on SDS-PAGE and performed a 
western blot using antibodies that recognize both the endogenous and the GFP-tagged 
protein. The total levels of SR proteins appear slightly over expressed in the 
respective transfected cell lines compared to the WT cells (Figure 2.1B-C). However, 
the endogenous protein level in the transfected cell lines is very low and almost 
negligible (Figure 2.1B-C). This is due to a well-known auto-regulation mechanism 
actuated by SR proteins on their own transcripts, which allows the cell to maintain 
each SR-protein at constant levels in the cell [24, 44]. The auto-regulation of SRSF3 
and SRSF7 is a strong indicator that these GFP-tagged SR proteins are fully 
functional in the cell lines and can bind their own transcript and down-regulate its 
levels. 
 
2.2 P19 Subcellular fractionation 
 
To determine whether SR proteins have distinct binding patterns during 
mRNA maturation, I developed a subcellular fractionation technique for P19 cells. 
Cell fractionation allowed me to obtain clean fractions from: cytoplasm (Cyt), 
nucleoplasm (Npl) and chromatin (Chr, also referred to as the nuclear insoluble 
pellet), and perform iCLIP on those samples. Recently, a number of papers have taken 
advantage of subcellular fractionation and deep sequencing to characterize RNA 
populations in the different fractions [1]. To date, no study has yet described a 
subcellular fractionation for P19 cells or iCLIP techniques combined with such 
fractionations.  
Furthermore, the optimization of fractionation methods for the specific cell 
line or organism is very important and key to generate proper experimental outcomes 
(chapter 1.6). Different methods exist as starting points for cellular fractionation. Two 
main features can identified among those protocols: firstly, that of sucrose cushion 
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based methods; and secondly, the detergent based methods. For a more complete 
explanation of these methods, refer to chapter 1.6.1 of the introduction.  
Figure 2.2: Schematic representation of P19 cell fractionation method. 
P19 cells were grown to 90% confluency and UV-crosslinked at 245 nm. Cells were collected and 
lysed, with mild detergent concentrations (0.3% NP-40). The lysate was centrifuged, and the 
supernatant containing the cytoplasm was separated from the pellet containing the nuclei. The pellet 
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was processed further by breaking the nuclear membrane. After centrifugation, the supernatant 
containing the nucleoplasmic fraction was collected in a separate tube. The pellet containing the 
nuclear insoluble fraction was washed twice and then sonicated to fully re-suspend the chromatin. The 
cytoplasmic, nucleoplasmic and chromatin fractions were then subjected to standard iCLIP. 
In my experiments, I employed different concentrations of detergent and 
mechanical sheering to lyse the cell membrane and subsequently break the nuclear 
membrane. A schematic of the final protocol is presented in Figure 2.2. To ascertain 
whether the protocol successfully separates the different compartments, with no cross-
contamination, I used Western blotting to discern between the three protein fractions,
I used GAPDH as a cytoplasmic marker, nuclear export factor (NXF1) as a 
nucleoplasmic marker and finally, RNA Polymerase II (RNA Pol II) and Histone H3 
as chromatin markers (Figure 2.3). 
Figure 2.3: Characterization of P19 cell fractionation. 
The subcellular fractionation purity was tested by detecting specific subcellular markers: Nuclear 
export factor 1(NXF1) was used as a nucleoplasmic marker; GAPDH was used as a cytoplasmic 
marker; RNA Polymerase II (RNA Pol II) and Histone H3 were used as chromatin specific markers. A)
Result from pre-optimization of the subcellular fractionation protocol. In B) the result of the final 
subcellular fractionation is shown. Every subcellular marker localizes properly and the fractions are 
pure. See the text for differences in protocols used to obtain A and B 
The development of a fractionation method for P19 cells required multiple 
steps of optimization. Figure 2.3A shows a blot for one of the initial fractionation 
attempts where the results, at this earlier stage, were not of sufficient purity. Here, I 
detected significant leakage of GAPDH from the cytoplasm to the chromatin fractions 
and I also found high levels of NXF1 in both the chromatin and nucleoplasm
fractions, whereas I expected to see NXF1 only in the nucleoplasm fraction. Finally, 
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there appears to be leakage of the Histone H3 from the chromatin to the cytoplasm 
fractions. However, after a multitude of alterations to the protocol, I obtained a much-
improved signal for all the markers (Figure 2.2B).  
In the improvement of the protocol I identified three stages, which seem to be 
fundamental in minimizing cross-contamination between the fractions. Specifically, 
these are steps 1, 4 and 5 described in Figure 2.2. In step 1 and until the cell 
membrane is broken and the cytoplasm collected, it is fundamental to delicately 
resuspend the cell pellet and keep it on ice, so as to avoid the breakage of the nuclear 
membrane that would result in subsequent leakage of the nucleoplasm into the 
cytoplasm fraction. Afterwards, in steps 4 through 5, it was important to use the 
appropriate concentration of detergent and number of washes to avoid high quantities 
of the nuclear fraction remaining in the insoluble (chromatin) fraction. Using 1.5% of 
NP-40 with two wash steps allowed for the cleanest results (Figure 2.3B). 
Thus, I could successfully fractionate P19 cells into three main fractions: 
cytoplasm, nucleoplasm and chromatin. As with every other fractionation technique, 
my fractionation method is not 100% pure, but as the data from Figure 2.3B indicates, 
it has achieved the highest obtainable purity at the moment with only minimal leakage 
between fractions. 
 
2.2.1 SRSF3 and SRSF7 are differently distributed in the cellular fractions 
 
SR proteins are mainly nuclear-localized proteins as illustrated using 
microscopy techniques and Western blot analysis [11, 12, 14, 16]. It is still unclear 
how the SR proteins, as a general class of proteins or specific members of the SR 
protein family (in my case SRSF3 and SRSF7), are distributed in chromatin with 
respect to other compartments. Thus far, it has been shown that SR proteins 
occasionally localize to the chromatin surrounding [14, 15]. To characterize such 
distributions I extracted protein samples from different compartments using my 
fractionation protocol (Figure 2.2). I extracted cellular fractions from cell lines with 
GFP tagged forms of SRSF3 or SRSF7. In this way I could test for the distribution of 
these two proteins, using a GFP antibody. The Western blot analysis shows that both 
proteins are detected at low levels in the cytoplasmic fraction with the majority of 
SRSF3 and SRSF7 localized to the nucleoplasm and chromatin (Figure 2.4A-B), 
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pointing toward high co-transcriptional activity for both SR proteins. The presence of 
signal for SRSF3 and SRSF7 in all three fractions prompted me to perform iCLIP 
experiments for these proteins on the above-mentioned fractions. 
Figure 2.4: Localization of SRSF7-GFP and SRSF3-GFP in different cellular compartments. 
A) Localization of GFP tagged SRSF7 proteins tested with western blot of protein samples from the 
three subcellular fractions, SRSF7-GFP was detected using specific anti-GFP antibody. B) Localization 
of GFP tagged SRSF3 proteins tested with western blot of protein samples from the three subcellular 
fractions, SRSF3-GFP was detected using a specific anti-GFP antibody. In both A and B equal amount 
of sample was loaded for each fraction. 
2.3 iCLIP for SRSF3 and SRSF7 in subcellular fractions  
I perform iCLIP on the fractionated samples from SRSF7-GFP and SRSF3-
GFP cell lines (as described in Figure 1.6), obtaining in this way the FRACKING data 
(Fractionation-iCLIP). Figure 2.5A-B displays the radioactive membrane, 
corresponding to the detection of a SDS-PAGE gel for the RNA-protein complexes 
extracted during iCLIP, as explained in Figure 1.6. The three fractions show an 
intensity profile that recapitulates the protein distribution indicated by previous 
Western blot analysis (Figure 2.4). This result confirms the RNA binding capability 
of the proteins tested. Figure 2.5C-D illustrates the final PCRs for the library 
preparations, with the samples divided into long (L), medium (M) and short (S) sized 
RNAs after reverse transcription, as shown in Figure 1.6. The three populations (L, M 
and S) are pooled and are then sent to the sequencing facility. For a complete 
explanation of the iCLIP protocol refer to chapter 1.5 of the introduction. 
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Figure 2.5: Quality controls performed through iCLIP. 
A) and B) show autoradiography analysis of SRSF7-RNA and SRSF3-RNA complexes, respectively, 
using denaturing gel electrophoresis and western blotting. Protein extracts were prepared by 
immunoprecipitating SRSF7 or SRSF3 from UV-cross-linked samples obtained from my subcellular 
fractionation. The dotted lines in A and B. represent regions used to isolate protein-RBPs complexes 
for downstream analysis. C) and D) PCR amplified products from the SRSF7 and SRSF3 iCLIP cDNA 
libraries, respectively, analyzed by denaturing gel electrophoresis. The RNAs from a selected region 
(see A and B) was reverse transcribed and three fractions of cDNA length were amplified before high-
throughput sequencing. Panels A) through D) show the above described analysis for the following 
fractions: cytoplasmic (Cyt), nucleoplasmic (Npl) and chromain (Chr).  
The library were then sequenced on the Illumina platform (75bp, single end 
reads), four replicates were sequenced for SRSF7 and eight for SRSF3, each replicate 
provided me with at least 20 million reads to be analyzed. The data was then mapped 
and analyzed using a bioinfomatic tool called iCOUNT. This bioinformatic tool was 
developed by the Ule lab [79] and was specifically developed to analyze iCLIP data. 
From the iCOUNT analysis, I obtained the dataset denoting significant binding sites 
(FDR < 0.05), for SRSF3 and SRSF7. I subsequently analyzed these two datasets to 
characterize differences in binding in the different fractions.  
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2.4 Analysis of SRSF7 FRACKING data  
 
iCOUNT analysis of SRSF7 data revealed the number of transcripts bound by SRSF7 
in the different fractions. From the iCOUNT analysis I also obtained different 
numbers of significant binding sites (FDR<0.05) for each fraction (Table 2.1). Here 
peaks indicate the number of nucleotides presenting significant SRSF7 binding. 
iCOUNT calculates these significant peaks by comparing the signal at the site with 
the background signal in the surrounding area of the gene. Only significant peaks 
were kept for the subsequent analysis. The number of peaks for each fraction is 
presented in the second column of Table 2.1.  
 
 Fraction Peaks  Clusters Transcripts 
SRSF7-Cyt 142,444 36,667 2,586 
SRSF7-Npl 130,680 34,943 2,588 
SRSF7-Chr 76,172 20,444 2,014 
 
Table 2.1: Results for FRACKING on SRSF7.  
The number of significant peaks for SRSF7 binding for cytoplasm (Cyt), nucleoplasm (Npl) and 
chromatin (Chr) are shown in the Peaks column. The Clusters column presents the number of 
significant clusters identified for the FRACKING data in each fraction. Finally, the Transcripts 
column presents the number of genes that exhibit SRSF7 binding in the different fractions. 
 
I detected the majority of peaks for SRSF7 in the cytoplasm, with slightly lower 
numbers in the nucleoplasm. The number of peaks for the chromatin fraction is lower 
than the number of peaks in the cytoplasmic and nucleoplasmic fractions. In this 
analysis I defined clusters as areas (of 15 nucleotides) presenting multiple peaks, 
creating in this way a high occupancy area of at least 15 nucleotides. From the 
number of clusters, (Table 2.1, third column) I detected that that SRSF7 peaks are 
focused around multiple high-occupancy binding sites. The number of high-
occupancy sites (peaks) that cluster in a 15nt neighborhood are grouped in a single 
cluster, the number of clusters presented in Table 2.1 was calculated in this way. 
Notably, SRSF7 binds to 2,014 transcripts in the chromatin fraction (Table 2.1, fourth 
column). More importantly, this data shows, that SRSF7 binds to the majority of its 
targets co-transcriptionally in vivo. At the same time I detected that SRSF7 binding 
increases to 2,588 transcripts in the nucleoplasm fraction and then stays roughly at 
that level through maturation and export with 2,586 transcripts as cytoplasmic targets. 
 40 
In conclusion, from this analysis I showed that SRSF7 has a strong co-transcriptional 
and post-transcriptional RNA-binding in the cell. 
After obtaining the number of targets and peaks bound by SRSF7 in the three 
analyzed fractions, I compared the set of targets bound between the different fractions 
to identify common and unique targets to every fraction (Figure 2.6A). In this 
analysis, SRSF7 binds as many as 2014 of its targets on the chromatin and 934 targets 
are maintained through the different fractions. Aside from the overlap between the 
fractions, each fraction had a pool of targets that were unique for that fraction. This 
binding might represent fraction-specific transcripts, or transcripts that present only 
weak or short-lived binding to SRSF7 and is thus, difficult to detect in all fractions. 
The absence of signal for some targets in particular fraction may be due to varying 
abundances of these transcripts between the three different RNA populations. To 
exclude or control for this possibility, RNA-seq will be carried out on these fractions 
in the future to fully elucidate the data. 
 To better characterize the different targets identified by FRACKING, I 
analyzed the Gene Ontology terms (GO-terms) of the transcripts common to all 
fractions, specifically, those targets that are present only in the nucleus (defined as the 
sum of targets from chromatin and nucleoplasm) and those that are exclusively 
cytoplasmic (Figure 2.6B). Interestingly, the targets bound by SRSF7 in all fractions 
are involved in RNA/nucleotide binding or are involved in RNA processing. This 
suggests that SRSF7 regulates efficient RNA maturation and export of these 
transcripts. Transcripts bound by SRSF7 only in the nucleus are involved in 
nucleotide binding, ion binding, transcription and DNA repair functions. It is possible 
that SRSF7 binds these transcripts in the nucleus and guides their maturation. 
Meanwhile, SRSF7 may not be needed for export and translation of such transcripts, 
which are activities that involve other proteins. Transcripts that were exclusively 
found to be bound in the cytoplasm might indicate novel binding of SRSF7 to these 
transcripts only after they are exported to the cytoplasm. Interestingly, these 
cytoplasmic targets are enriched for transcripts encoding transmembrane proteins and 
transmembrane transporters, which are usually located in cytoplasmic organelles or in 
the plasma membrane. At this moment, the function of SRSF7-binding on these 
transcripts is still unclear. 
 Within protein-coding genes, identification of the transcript regions bound by 
SRSF7 is of functional importance. Furthermore it has been shown that SR proteins 
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bind to different extents within different transcript regions along their target 
transcripts [24]. To see whether I could detect a particular binding pattern along 
different regions of RNA (e.g. UTRs, introns, ORF, ncRNAs…) and whether this 
binding is different between the three fractions, I explored the distribution of SRSF7 
binding peaks in the transcriptome (Figure 2.6C). SRSF7 binds to distinct parts of 
RNA in each fraction. SRSF7 binding within chromatin is mainly concentrated in 
introns and ncRNAs. Intronic binding is relatively lower in the cytoplasm than in the 
chromatin. This is expected, because chromatin is enriched in unspliced RNAs. 
Nevertheless the majority of cytoplasmic crosslink sites originate from introns, which 
is surprising. I will focus more in detail on this data in chapter 2.4.3. Conversely, I 
detected an opposite trend for exon binding (ORF), where SRSF7 interaction with 
exons is enriched in the cytoplasm while exon binding is much reduced in the 
chromatin fraction, possibly accounting for the higher fraction of exons present in 
cytoplasmic mRNAs. As shown in Figure 2.6, SRSF7 does not only contact exons 
and introns of its target transcripts, SRSF7 binds to UTRs, preferentially binding 
3’UTRs over 5’UTRs. SRSF7 binding to 3’UTRs is relatively higher in the 
cytoplasmic fraction with the quantity of binding decreasing in the nucleoplasmic and 
the chromatin fractions.  
Analysis of SRSF7 binding to ncRNAs in the different fractions reveals 
fraction specific binding to different ncRNAs. To better characterize the ncRNA 
distribution and understand the differences in the fractions, I decided to analyze this 
binding pattern more closely and divide the ncRNA binding into different sub-classes 
(Figure 2.6D). I could show that the high cytoplasmic ncRNA signal can be attributed 
to the binding of SRSF7 to mitochondrial ncRNAs (mt-tRNA and mt-rRNA from 
Figure 2.6D). Mitochondrial RNA accounts for more than 40% of the ncRNA binding 
for SRSF7 in this fraction. It is important to note that in my fractionation method, 
during the lysis of the cell membrane, I also have lysed the mitochondria, which 
would account for the presence of mitochondrial RNAs in the cytoplasmic fraction. 
Nevertheless, this strong enrichment could indicate a novel function of SRSF7 on mt-
RNAs.  
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Figure 2.6: Analysis of the FRACKING binding targets of SRSF7 and the binding distribution in 
different classes and transcript regions.  
A) Comparison of annotated transcripts with significant levels of SRSF7 binding in chromatin (Chr), 
nucleoplasm (Npl) or cytoplasm (Cyt). B) GO-term analysis for SRSF7 targets common to all 
fractions, unique for the nucleus (chromatin + nucleoplasm) and unique for the cytoplasm. C) 
FRACKING peaks were divided into specific groups depending on the biotype of their respective 
transcript. Protein-coding transcripts were further subdivided to 3’ and 5’ untranslated regions (UTRs), 
open reading frame (ORF) and introns. The region defined as “Others”, represent binding of SRSF7 to 
any un-annotated intergenic region. Bars represent relative peak abundance for: cytoplasm (Cyt), 
nucleoplasm (Npl) and chromatin (Chr) fractions, as stated in the legend. D) Relative distribution of 
significant tags within ncRNA subclasses. 
 
SRSF7 binds equally to the other different classes of ncRNAs, except for 
snoRNAs. In fact, SRSF7 has high binding levels to snoRNAs in the chromatin and 
nucleoplasmic fractions only (Figure 2.6D). This high binding preference might 
reflect a previously unknown activity of SRSF7 in the maturation of snoRNAs. 
Furthermore, it seems that SRSF7 binds co-transcriptionally (on the chromatin) to the 
snoRNAs and binds with lower levels to snoRNAs in the nucleoplasm. The great 
difference in the percentages of snoRNA binding, for the different fractions, is 
important here, as it shows, once again, that the leakage of the nuclear fractions 
during the fractionation is minimal.  
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To fully charachterize the data obtained by FRACKING, a comparison of 
transcripts detected in all fractions with the whole cell is informative. I combined the 
target transcripts obtained from my different fractions (Figure 2.6 A), obtaining in this 
way a set of targets originating from the whole cell. I subsequently compared these 
targets to the one identified by standard iCLIP of SRSF7 (Müller-McNicoll, data 
unpublished; Figure 5.3). The two datasets showed a high level of overlap, with only 
a small subset of targets being unique to the FRACKING data, standard iCLIP 
identified a higher number of targets. Many iCLIP targets identified were the same 
identified via FRACKING. It is not surprising that standard iCLIP can identify a 
higher number of targets since these samples undergo a lower level of processing. It is 
possible that part of the sample is lost during the fractionation protocol. Nevertheless, 
my pooled FRACKING data nicely recapitulate standard iCLIP data. This analysis 
shows that FRACKING can be confidently used instead of standard iCLIP, since it 
provides the same results and also adds information regarding where in the cell and at 
what stage of maturation RNA-protein interactions are taking place. 
In conclusion, my analysis of FRACKING data for SRSF7 yields important 
results and different patterns of SR-protein-RNA binding. The differences in levels of 
the various biotypes recovered (e.g. snoRNAs, mt-ncRNAs, 3’UTRs) further validate 
the success of the subcellular fractionation in the P19 cells. In order to better 
understand the difference in snoRNA signals, I carried out a more in depth analysis. 
The results are given in the next section. 
 
2.4.1 FRACKING shows binding of SRSF7 to snoRNAs in the nucleus 
 
In my analysis, I detected that snoRNAs are highly bound by SRSF7 with 
respect to other classes of ncRNAs (Figure 2.6D). This seems to be a more 
pronounced phenomenon in the chromatin than in the nucleoplasmic fraction. To 
better understand how the signal actually distributes along snoRNAs, I looked at 
specific snoRNA clusters that showed high enrichment in binding.  Single gene 
example with associated iCLIP tags for GNB2L1 is given in Figure 2.7A. GNB2L1 
contains two snoRNAs within its introns, Snord95 and Snord96, interestingly for 
these two snoRNAs the signal is predominantly nuclear (nucleoplasm and chromatin) 
with a complete absence of signal in the cytoplasm. This behavior is even more 
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visible when I looked more closely into the genomic region encoding for Snord95 
(Figure 2.7B) where I detected not only a high SRSF7 binding peak in the middle of 
the Snord95 sequence, but also a notable presence of a sharp binding peak just prior 
to the start of the mature Snord95. This latter example suggests a possible function of 
SRSF7 in the maturation of this snoRNA. 
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Figure 2.7: SRSF7 FRACKING signal along the GNBL1L transcript and intronic snoRNAs.  
A) UCSC genome browser view of FRACKING data along GNBL1L transcript. GNBL1L transcript 
main isoform is presented in black boxes, and black lines, alternative isoforms and/or ncRNAs are 
presented as white boxes and black lines. Thinner boxes represent untranslated regions. Mammal cons, 
shows the mammalian conservation score for the region here shown: gray areas denote high 
conservation score; brown area denote low conservation score. B) Enlargement of the dashed box 
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region of figure A), SRSF7 binding signal along the snoRNA SNORD95. C) UCSC genome browser 
view for FRACKING data along the snoRNA SNORD13.  
 
A similar peak can be observed in many snoRNAs (Figure 2.7C). For example 
in the case of Snord13 I also detected a low binding signal in the cytoplasm for this 
snoRNA, possibly attributable to a small fraction of particular snoRNA briefly 
shuttling to the cytoplasm or to a minor leakage of the nuclear signal into the 
cytoplasm.  
To gain insight into the global nature of SRSF7 binding to snoRNAs, I plotted 
the average coverage of the binding signal for SRSF7 along the sequence of annotated 
snoRNAs and surrounding areas (±500 nt) (Figure 2.8A). From the coverage plot I 
detected that the majority of SRSF7 binding takes place in the middle of the mature 
snoRNA sequence and that it mostly occurs on chromatin (for an explanation 
regarding the coverage plot and heatmap analysis refer to chapter 4.8 of materials and 
methods).  
Additionally, I detected a fairly strong peak of binding near the 5’ end of the 
snoRNAs, which is not present at appreciable levels in the other two fractions. 
Importantly, when I plotted, as a heatmap, the binding signal along all annotated 
snoRNA sequences (±500 nt of surrounding areas), (Figure 2.8B) I could detect 
differences in binding signal between fractions.  
The data presented here confirms that SRSF7 can bind snoRNAs in chromatin, 
and possibly play a role in guiding their biogenesis and/or stability. 
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Figure 2.8: Analysis of SRSF7 binding along snoRNA regions in the different fractions. 
A) Average coverage plot for SRSF7 binding on all annotated snoRNAs in chromatin (Chr, in green), 
nucleoplasm (Npl, in purple) and cytoplasm (Cyt, in orange), y-axis values are the log2 of the binding 
signal on snoRNA divided by the total signal, total signal is the sum of binding along the whole tested 
region. In the x-axis we have the genomic location of mature snoRNA sequence from 5’End to 3’End, 
±500 nt on each side. B) Heatmap of the average binding signal along all annotated snoRNA sequences 
±500 nt; each row represents a single snoRNA, values are log2 of the binding signal. 
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2.4.2 MALAT1 is highly bound by SRSF7 in all fractions 
 
From the reanalysis of recent, unpublished, iCLIP data produced in our lab 
(Michaela Muller-McNicoll), I could show that all SR proteins tested to date (SRSF1 
through SRSF7) strongly bind MALAT1 (Figure 2.9A). Here, I showed that SRSF7 
binds with higher levels to MALAT1 in comparison to other SR proteins. Given these 
data, I decided to analyze the binding of SRSF7 to MALAT1 using my FRACKING 
data (Figure 2.9B). 
 
 
Figure 2.9: SR-protein binding to MALAT1 lncRNA. 
A) iCLIP data for all the canonical SR proteins (SRSF1 through SRSF7) (Müller-McNicoll and 
Valentina Botti, data unpublished). Binding data from Coilin [78] iCLIP and GFP fused to a nuclear 
retention signal (GFP-NLS) iCLIP are presented as negative controls for binding to MALAT1 B) Pie-
chart presenting SRSF7 binding tag number for each fraction obtained by FRACKING. 
 
SRSF7 binding to MALAT1 showed to be present at high levels also in the 
cytoplasm. Analysis of the total distribution of peaks, in the different fractions, on 
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MALAT1 for SRSF7 is shown in the pie-chart in Figure 2.9C.  Around 77% of the 
binding of SRSF7 to MALAT1 occurs in the nucleus (normalization of the number of 
tags for the total amount of tags present in each fraction did not influence the result 
shown, as presented in Figure 5.5).  It is interesting to note that about 23% of this 
binding occurs in the cytoplasm. In fact, MALAT1 is thought to be a nuclear lncRNA, 
as it contains a nuclear retention signal in its sequence. Recent reports show the 
presence of MALAT1 RNA in ribosome profiling in both mammalian and yeast cells 
[89, 90]. SRSF7 strongly binds MALAT1 in the nucleus, which is then followed by 
shuttling of a small contingent of these transcripts to the cytoplasm. This data shows 
that FRACKING is capable of identifying rare and volatile events that occur in 
protein-RNA binding interactions with different RNA species. 
 
2.4.3 FRACKING reveals high SRSF7 binding to introns 
 
From the SRSF7 FRACKING data, I identified that SRSF7 binds strongly to 
introns, (Figure 2.6C and Figure 2.10A). It is important to keep in mind, though, that 
even if exons have a smaller amount of binding signal, they also account for a smaller 
part of the transcripts. Furthermore, the FRACKING binding signal can be 
normalized for the length of the transcript features analyzed. Using this method, I 
obtained a plot that better represents the binding of SRSF7 along introns and exons 
(Figure 5.1A, Appendix). Once binding is normalized to account for the difference in 
length of the two features, I have a much smaller intronic-binding signal, due to their 
longer sequences. On the contrary, now exons are more highly represented in my data 
as such sequences present a very small part of the transcriptome. However when 
looking at the shear number of binding sites, more intronic sites are bound by SRSF7, 
indicating that, I have a significant number of SRSF7-binding sites in introns.  
To further understand SRSF7 binding of exons and introns, I decided to look 
only at the average binding signal along exon-intron junctions where the binding 
signal gives a better idea of SRSF7 binding distribution along pre-mRNAs and 
mRNAs. Figure 2.10A-C shows the plotted average profile for all SRSF7-bound 
genes of cross-link signal along all exon-intron and intron-exon junctions. In all 
fractions, the maximum signal peak lies in the exon area, whereas the intronic signal 
varies for each fraction. Interestingly, the majority of the signal lies within 100-150nt 
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from the splicing sites, recapitulating SRSF7 function as a splicing factor. I detected 
that the chromatin fraction has an equal signal in both the exons and introns (Figure 
2.10A). The intronic binding signal greatly diminishes in the nucleoplasmic fraction 
(Figure 2.10B). This culminates in having a very low, almost negligible intronic 
signal in the cytoplasm (Figure 2.10C). The decrease in SRSF7 intron binding 
between fractions is due to the gradual removal of introns from the transcripts 
operated by splicing. Many studies have shown that splicing initiates and often 
completes during transcription [1, 36, 91].  
My data shows, in vivo, and in a genome-wide scale that SRSF7 binds to its 
targets co-transcriptionally and it presents high binding signal to both introns and 
exons, possibly helping co-transcriptional splicing to take place.  
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Figure 2.10: Meta-analysis of SRSF7 average binding to exon-intron, intron-exon junctions for 
all transcripts bound in the different fractions. 
A) through C) show SRSF7 binding (number of crosslink sites) averaged for all bound transcripts and 
centered around the exon-intron junction (left) and intron-exon junction (right). The 0 position in the 
plots (black line) represent the indicated 5’ or 3’ splice site; y-axes represent the number of crosslink 
sites. In A) are presented the plots for the chromatin fraction (green); in B) plots for the nucleoplasmic 
fraction (purple) and in C) the plots for the cytoplasmic fraction (orange). 
 
2.4.4 Intron-retained isoforms bound by SRSF7 are exported to the cytoplasm 
 
Because transcripts are expected to be fully spliced in the nucleus before being 
exported to the cytoplasm, intron binding is expected to be nuclear. However, analysis 
of SRSF7 binding revealed intron binding in the cytoplasm (Figure 2.6C and Figure 
2.10A-C). Certainly, these signals are much lower than those detected in the 
nucleoplasm and chromatin fractions (Figure 2.6C, Figure 2.10A-C, and Figure 
2.11A). To better understand this cytoplasmic data, I examined a subset of introns that 
are bound by SRSF7 in the cytoplasm. To better characterize these data I analyzed the 
list of all genes with intron signal in the cytoplasm, I identified 232 introns that 
possessed SRSF7 binding signal in the cytoplasm (Figure 2.11A). A surprising 
number of these introns present higher conservation between mammalian species 
(UCSC Genome Browser [92]), compared to the flanking introns, having at least 10% 
nucleotide identity between vertebrates, where usually introns present 2.1% of 
nucleotide identity [93]. Through manual analysis of conservation, I could detect that 
78% of these introns are highly conserved, compared to what is commonly seen for 
introns (Figure 2.11B). In addition, 50% of the remaining introns with no appreciable 
conservation also had very low signal, being nearly undetectable (i.e. less then 4 
cross-link sites along the full intron). Focusing on introns with high conservation, one 
possibility is that a number of these cytoplasmic intron signals are derived from novel 
alternative exons, alternative termination sites, and alternative 3’UTRs. In all cases, 
SRSF7-binding is limited only to a small region within the intron which could be 
consistent with this proposal. Alternatively, intron binding in the cytoplasm could 
reflect nonsense mediated decay (NMD), in which transcripts containing premature 
stop codon are degraded in the cytoplasm (for more details on NMD refer to section 
1.3.1). 
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Figure 2.11: SRSF7 binding to intronic regions in the three fractions and characterization of 
these regions. 
A) Number of introns with SRSF7 binding identified in the different fractions by FRACKING. B) 
Characterization of the conservation (at least 10% nt identity) for introns that present intronic binding 
of SRSF7 in the cytoplasm (low signal intron are defined as intronic region with a total signal lower 
than 4 crosslink sites). 
 
To fully understand and validate these results, in particular the presence of 
retained introns with high conservation in the cytoplasm, I focused on several highly 
conserved SRSF7-bound introns in the following section.  
 
2.4.5 SRSF7 strongly binds to its own transcript 
 
 To understand whether SRSF7 can regulate its own transcripts in the different 
cell fractions, I focused specifically on SRSF7 binding within the SRSF7 transcript 
(Figure 2.12A). I detected that SRSF7 strongly binds its own transcript during 
maturation. Interestingly, the SRSF7 transcript is the top-binding target for its own 
protein in all three fractions (Table 5.1 of the appendix). This reflects the important 
role that SRSF7 plays in tightly regulating its own transcript during all stages of 
maturation. 
From the data, I also determined interesting differences in binding between 
different fractions. Specifically, 5’UTR-binding is mostly enriched after transcription 
in the cytoplasmic and nucleoplasmic fractions. Furthermore, the 5th intron in SRSF7 
displays high co-transcriptional (chromatin) signal with nearly negligible cytoplasmic 
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signal (Figure 2.12A). I could also detect that even though the binding is distributed 
all along the ORF and UTRs of the transcript, the majority of SRSF7-binding occurs 
at the 3rd intron of SRSF7 (Figure 2.12A-B). This 3rd intron contains the previously 
described poison exon (in red in Figure 2.12A-B). With a closer view on this intron 
(Figure 2.12B), I could show that the binding is not restricted only to the poison 
cassette, as previously illustrated, for SRSF3 and SRSF4 [24], but actually extends 
along the entire 3rd intron (Figure 2.12B). Even more striking is that this binding is 
maintained at very high levels even in the cytoplasm. The presence of SRSF7-binding 
on the fully retained intron in the cytoplasm is surprising as retained intron species are 
expected to remain only in the nucleus. Importantly the conservation of the full 3rd 
intron is significantly high (~90%) (Figure 2.12A-B, gray trace) when compared to 
the surrounding introns. From analyzing the binding data for NXF1 in this area 
(Muller-McNicoll, data unpublished), I detected that NXF1 is also capable of binding, 
with high levels, within the 3rd intron of SRSF7 (Figure 2.12B, blue trace). These data 
suggest that the SRSF7 isoform containing a retained, full third intron, can be 
exported to the cytoplasm.  
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Figure 2.12: SRSF7 binding on its own transcript detected by FRACKING. 
A) USCS genome browser view of SRSF7 binding on its own transcript. SRSF7 transcript main 
isoform is presented as black boxes (exons), and black lines (introns), alternative isoforms and are 
presented as white boxes and black lines. Thinner boxes represent untranslated regions. The red box 
represents the SRSF7 poison exon cassette. B) USCS genome browser view for the 3rd intron of SRSF7. 
Trace in blue obtained from standard iCLIP for nuclear export factor 1 (NXF1) (unpublished data from 
Michaela Müller-Mcnicoll and Valentina Botti).   
 
 
Importantly, the intron-retained isoform also contains a PTC near the 
beginning of the retained intron, allowing this isoform to be regulated by NMD or 
another RNA stability mechanism in the cytoplasm. For this reason, I deemed this 
intron the  “poison intron”. To be fully confident that such an isoform is exported and 
regulated by NMD I decided to test two main hypotheses: 
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1. The poison intron-containing isoform of the SRSF7 transcript can be detected 
in the cytoplasm without using iCLIP related techniques 
2. The poison intron triggers NMD 
 
To test hypothesis 1, I designed specific primers that adapt to the exons 
flanking intron 3 and primers that adapt to the center of intron 3, as denoted by the 
arrows in Figure 2.13A.  
 
Figure 2.13: Validation of the presence of SRSF7 intron retained species in the cytoplasm, and 
their sensitivity to NMD inhibition. 
A) Schematic of the SRSF7 transcript region shown in Figure 2.12B. Arrows represent regions where 
PCR primer sequences were designed to anneal. Red boxes represent the poison exon region. B) 
Validation of the cytoplasmic presence for intron retained specie of the SRSF7 transcript, detected by 
RT-PCRs of cytoplasmic mRNAs with primers for exons and the poison exon cassette region. Top 
band (in top and bottom panels) represent full intron retained species and bottom band (in top and 
bottom panels) represent poison cassette containing isoform. C) Test of NMD sensitivity for intron 
retained and poison cassette isoforms for SRSF7. NMD sensitivity was tested by comparing changes in 
the levels for different isoforms before and after using the chemical inhibitor of translation, 
cycloheximide (CHX) by RT-PCR of total RNA. Primers used were placed on exon 3 and exon 4 
(respectively) to obtain all possible SRSF7 isoforms. GAPDH was used as control.  
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To validate the presence of the poison intron species in the cytoplasm, I used a 
crosslink-independent technique that involved extracting cytoplasmic mRNA without 
first performing UV crosslinking. I reverse transcribed the RNAs and performed two 
PCRs using primer pairs, 1+4 and 2+3 (Figure 2.13A) that are complementary to exon 
and intron regions. This allowed detection of both the poison exon and the full intron 
at the same time, from both ends. From these cytoplasm-RT-PCRs (cyto-RT-PCR), I 
could show that both the fully unspliced and the poison exon containing isoforms are 
detectable in the cytoplasm, with both pairs of primers (Figure 2.13B). This indicates 
that the poison intron isoform is indeed exported to the cytoplasm, even if it is present 
at lower concentrations than the poison cassette isoform. This is shown from the 
difference in intensities observed between the top and bottom bands in Figure 2.13B. 
In conclusion, both poison intron isoforms are exported to the cytoplasm.  
 To test whether both the poison exon and poison introns are subjected to 
NMD, I proceeded to inhibit NMD. For this experiment, I treated the cells with the 
chemical agent, cycloheximide (CHX), which inhibits translation. As NMD requires 
translation initiation, treatment of the P19 cells with CHX should stabilize the NMD 
sensitive isoforms. To ascertain whether the CHX treatment effectively stabilized 
both SRSF7 poison intron and exon isoforms, I performed RT-PCR of total RNA 
extracted from CHX-treated or control samples. The PCR was performed using 
primers 1+2 (Figure 2.13A). These primers complement exon 3 and exon 4, 
respectively, and can amplify three different SRSF7 isoforms: the poison intron-
containing isoform, the poison exon-containing isoform, and the fully spliced exon4-
exon5 isoform. The results from this RT-PCR are presented in Figure 2.13C. By 
comparing the CHX-treated and untreated samples, I detected a change in the 
intensity of the poison exon-containing isoform, indicating that CHX indeed stabilizes 
this isoform; therefore, it should be targeted by NMD. Furthermore, I did not detect a 
change in the intensity of the poison intron band. As expected, the GAPDH-control 
and the fully spliced isoform did not show changes in stability upon CHX treatment.  
I was able to validate the presence of the poison intron species in the 
cytoplasm. Further experiments are required to fully investigate a potential role of 
NMD in regulating the poison intron isoform levels. I showed here that my data can 
be validated and I confirmed, using cyto-RT-PCR, that introns containing isoform 
could indeed be exported to the cytoplasm. 
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2.4.6 Highly conserved introns bound by SRSF7 are exported 
 
The SRSF7 transcript is not the only example of a transcript with highly 
conserved and retained introns that seem to be also exported. As previously shown, I 
identified more than 200 transcripts that have cytoplasmic-SRSF7 binding along an 
intron and 78% of these introns are actually highly conserved between mammals 
(Figure 2.11B). To understand if SRSF7 binding behavior along these transcripts is in 
any way similar to the binding observed on its own transcript, I decided to focus on 
three other highly conserved intron transcripts with high binding signal in all three 
fractions. These transcripts include:  ARGLU1, SRSF3 and HNRNPH1.  
FRACKING data for SRSF7-bound transcripts is shown in Figure 2.14A-C, 
here I detected significant binding levels of SRSF7 along the highly conserved introns 
of these transcripts in the cytoplasm. SRSF7 has lower binding levels along these 
transcripts when compared to the levels detected on its own transcript. This probably 
reflects, once again, the importance for SR proteins to regulate or titrate their own 
levels.  
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Figure 2.14: Examples of SRSF7 binding to highly conserved introns in all fractions. 
A) UCSC genome browser view for the binding of SRSF7 on ARGLU1 transcript, that presents high 
SRSF7 binding along highly conserved introns in the cytoplasm. B) UCSC genome browser view for 
the binding of SRSF7 on the SRSF3 transcript. C) UCSC genome browser view for the binding of 
SRSF7 on the HNRNPH1 transcript that presents high SRSF7 binding along highly conserved intron in 
the cytoplasm. A) through C) For each transcript, the main isoform is presented as black boxes (exons), 
and black lines (introns), alternative isoforms are presented as white boxes and black lines. Thinner 
boxes represent untranslated regions. The red box represent poison exon cassette, when present. 
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I could detect SRSF7 binding to the SRSF3 transcript, along its third intron, 
which contains the SRSF3 poison exon cassette (Figure 2.15A, red box). The poison 
cassette exon, as mentioned in chapter 1.2, is a common feature of all SR proteins, 
which allows them to regulate their transcript levels in the cell. This SRSF7 binding 
shows that SRSF7 can possibly regulate the levels of SRSF3 by influencing the 
stability of its transcripts. 
As explored previously in chapter 2.4.5, I proceeded to verify the following 
hypotheses:  
1. The intron retaining isoform of each transcript tested can be detected in the 
cytoplasm without using iCLIP related techniques. 
2. The intron retained isoform of each tested transcript triggers NMD. 
 
Here I employed Cyto-RT-PCRs for SRSF3, ARGLU1 and HNRNPH1 as can 
be seen in Figure 2.15A. For all three transcripts examined, I validated the presence of 
their intron-containing isoforms in the cytoplasm, even if the levels of these isoforms 
were quite low.  
Since the poison intron of SRSF7 seemed to be insensitive to CHX treatment, I 
tested whether these three transcripts are influenced by translation inhibition (Figure 
2.15B). From these analyses I did not detect any effect of the CHX treatment for the 
poison intron isoforms, as observed for SRSF7. The only isoform that showed any 
detectable accumulation, upon CHX treatment, was the poison exon isoform of 
SRSF3. 
In conclusion, the FRACKING data allowed me to identify and validate that 
highly conserved introns bound by SRSF7 are not always spliced out, and that the 
isoforms containing these retained introns can be exported to the cytoplasm, possibly 
via their interaction with SR proteins. 
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Figure 2.15: Validation of the presence of intron retained species in the cytoplasm their 
sensitivity to NMD inhibition. 
A) Validation of the cytoplasmic presence for intron retained transcript species. These isoforms were 
detected by RT-PCRs of cytoplasmic mRNAs, using primers for exons and intronic regions. B) NMD 
sensitivity was tested by comparing changes in levels for different isoforms before and after using the 
chemical inhibitor of translation cycloheximide (CHX) by RT-PCR of total RNA. GAPDH was used as 
control. 
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2.5 Analysis of SRSF3 FRACKING data  
 
Analysis of SRSF3 FRACKING data through iCOUNT revealed the number of 
transcripts bound by SRSF3 in different fractions (Table 2.2). Only those peaks with 
high significance were kept for the subsequent analysis. Here peaks represent the 
number of nucleotides presenting significant SRSF3 binding. 
 
 Fraction Peaks  Clusters Transcripts 
SRSF3-Cyt 151,643 37,411 3,931 
SRSF3-Npl 320,119 73,810 5,689 
SRSF3-Chr 264,515 55,068 3,761 
 
Table 2.2: Results for FRACKING on SRSF3.  
The number of peaks for SRSF3 binding for the cytoplasm (Cyt), nucleoplasm (Npl) and chromatin 
(Chr) are shown in the Peaks column. The Clusters column presents the number of significant clusters 
identified for the FRACKING data in each fraction. Finally, the Transcripts column presents the 
number of genes that exhibit SRSF3 binding in the different fractions. 
 
The number of binding peaks for SRSF3 is much higher for the chromatin fraction, 
than what was detected for SRSF7. SRSF3 binds as many as 3,761 genes co-
transcriptionally, this number is significantly higher than what I detected for SRSF7 
FRACKING data (SRSF7 binds 2,014 transcripts in the chromatin). It seems as if 
SRSF3 is more active co-transcriptionally than SRSF7. The data also shows that 
SRSF3 possibly aids in exporting a large number of transcripts (with at least 3,931 
transcripts bound in the cytoplasm).  Therefore, the difference in the number of genes 
bound from the nucleoplasm to the cytoplasm might be due to SRSF3 falling off 
transcripts upon reaching the cytoplasm. From this analysis, I showed that SRSF3 
binds in the chromatin many transcripts and that this interaction is present also in high 
level for the cytoplasmic fraction. 
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Figure 2.16: Histograms representing the binding location, in different genomic regions obtained 
by FRACKING for SRSF3. 
A) Comparison of annotated transcripts with significant levels of SRSF7 binding in chromatin (Chr), 
nucleoplasm (Npl) or cytoplasm (Cyt). B) GO-term analysis for SRSF7 targets common to all 
fractions, unique for the nucleus (chromatin + nucleoplasm) and unique for the cytoplasm. C) Peaks 
were divided into specific groups depending on the biotype of their respective transcript. Protein-
coding transcripts were further subdivided to 3’ and 5’ untranslated regions (UTRs), open reading 
frame (ORF) and introns. The region defined as “Others” represent binding of SRSF3 to any un-
annotated intergenic region. Bars represent relative peak abundance for: cytoplasm (Cyt), nucleoplasm 
(Npl) and chromatin (Chr) fractions, as stated in the legend. D) Relative distribution of significant tags 
within ncRNA subclasses. 
 
 
Analysis of the overlap of targets between different fractions (Figure 2.16A) 
allowed me to confirm that the majority of transcripts bound by SRSF3 in the 
chromatin are then exported while still bound to SRSF3. Here, I detected that SRSF3 
binding is maintained from the chromatin through to the cytoplasmic fraction for 
2050 of SRSF3 target RNAs.  Interestingly each fraction showed a unique pool of 
targets that were specific found within that fraction. This binding potentially suggests 
that SRSF3 binds to certain targets in a fraction-specific manner.  Additionally, some 
transcripts may have only weak or short-lived binding to SRSF3, making it difficult to 
detect such interactions throughout all fractions.  
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 Analysis of the Gene Ontology terms (GO-terms) for transcripts of the 
different fractions aids in characterization of the FRACKING data. The transcripts 
within the nucleus comprised the sum of targets from both the chromatin and 
nucleoplasmic fractions and those fractions that are exclusively cytoplasmic (Figure 
2.16B). The targets bound by SRSF3 in all fractions are usually involved in 
nucleotide binding or RNA processing. Transcripts bound by SRSF3 only in the 
nucleus code for proteins with functions in RNA processing, splicing and also include 
nuclear lumen proteins. It is possible that SRSF3 is not needed to help the export of 
these transcripts to the cytoplasm. As seen for SRSF7, I identified a subset of 
transcripts bound by SRSF3 only in the cytoplasm.   More specifically, these 
transcripts encoded cytoplasmic proteins such as organelle membrane proteins, RNA 
transport proteins, and transmembrane proteins. 
 Within protein-coding genes, identification of the transcript regions bound by 
SRSF3 is of functional importance. It is known for some SR proteins that they can 
bind to different extent within different regions along their target transcripts [24]. To 
see whether I could detect a particular binding pattern along different RNA regions 
(e.g. UTRs, introns, ORF, ncRNAs, etc) and whether this binding is different in the 
three fractions, I explored the distribution of SRSF3 binding peaks in the 
transcriptome (Figure 2.16C). As expected from the data in Table 2.2, SRSF3 exhibits 
significant chromatin binding in most transcript regions, but such binding is mainly 
concentrated in introns. SRSF3 binds to introns decreases from the chromatin to 
cytoplasmic fractions. I detected an opposite trend for SRSF3 exon binding (ORF), 
where the majority of binding taking place in the cytoplasm. With this data I showed 
that SRSF3, as with SRSF7, remains bound to many exons even after intron splicing 
is completed, possibly to facilitate export. In addition to intron and exon binding, 
SRSF3 binds to UTRs (Figure 2.16A). SRSF3 interaction with 5’UTRs appears to be 
slightly enriched in the cytoplasm, yet at the same time, the amount of binding in 
these regions is relatively low. On the contrary, I detected an appreciable level of 
binding for SRSF3 on 3’UTRs, mostly in the cytoplasm. 
Analysis of the ncRNA binding by SRSF3 in different fractions reveals 
significant differences to SRSF7. SRSF3 crosslinking to ncRNAs showed enrichment 
in the cytoplasmic fraction (2.16C). Given these results I decided to further analyze 
SRSF3 binding on different class of ncRNAs for the three fractions (Figure 2.16D). 
More than 50% of the cytoplasmic ncRNA signal comes from mitochondrial (mt) 
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ncRNAs (mt-rRNA and mt-tRNA of Figure 2.16D). SRSF3 binding on ncRNA 
presented some differences to SRSF7 (Figure 2.6D), in fact I detected SRSF3 
nucleoplasmic binding on mt-rRNAs, which I did not detect for SRSF7. This is 
unlikely to result from fraction cross-contamination since I do not detect a similar 
pattern for mt-tRNAs binding (Figure 2.16B). Furthermore lncRNA were bound by 
SRSF3 with a more pronounced pattern than what I detected for SRSF7 (Figure 
2.6D). Finally SRSF3 showed extensive binding along snoRNAs in the chromatin 
fraction, with as much as 51% of the total chromatin ncRNA signal belonging to 
snoRNAs. Meanwhile, the nucleoplasmic binding signal of SRSF3 on snoRNAs 
presented low levels (Figure 2.16B) compared to SRSF7 (Figure 2.6D). In conclusion, 
each SR-protein studied demonstrated different associations with mt-ncRNAs, 
snoRNAs, and lncRNAs when comparing the different fractions. These results further 
indicate that FRACKING can distinguish between diverse binding characteristics for 
different proteins of the same family. 
To fully characterize the data obtained by FRACKING, a comparison of 
transcripts detected in all fractions with whole cell iCLIP is fundamental. As 
presented in section 2.4, I tested whether the FRACKING data obtained for SRSF3 
are comparable to standard-iCLIP data (indicated as Total-iCLIP in Figure 5.4). In 
this case I could compare my data to both published, but older, iCLIP data [24] and 
newly produced data (Müller-McNicoll, data unpublished). First, I tested whether the 
two standard-iCLIP experiments identified concordant targets (Figure 5.4A). The two 
datasets showed a high level of concordance, but the older dataset had a number of 
targets that were ten times lower than the new dataset; this is due to the great 
improvements made recently in deep-sequencing techniques [94]. Comparing the 
combined target transcripts obtained from my different fractions with the published 
dataset showed that both FRACKING and standard-iCLIP have overlapping targets 
(Figure 5.4B-C). The differences observed are only in a subset of targets, and the 
number of these targets is in proportion similar to what I observed when comparing 
the two standard-iCLIP protocols (Figure 5.4A). This analysis proves that 
FRACKING is a powerful technique that can easily recapitulate results obtained by 
standard iCLIP and provide supplementary information regarding the subcellular 
location of binding, which are impossible to obtain using standard iCLIP experiments. 
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2.5.1 SRSF3 strongly binds snoRNAs and their surrounding introns in the 
chromatin 
 
  Analysis of SRSF3 binding along snoRNAs revealed that such binding 
behavior is greatly enriched in the chromatin fraction. Identifying how SRSF3 
binding to snoRNAs is distributed is of fundamental importance to characterize 
SRSF3 action of these ncRNAs. To do so I generated similar analyses to those 
previously shown for SRSF7 (Figure 2.17 and 2.18A-C). Figure 2.17 illustrates an 
example of snoRNA clusters that are bound by SRSF3. Here, I detected that the 
SRSF3 protein truly binds snoRNAs mostly in the nucleus with a preference for 
chromatin binding. The cytoplasmic signal is either completely absent or significantly 
lower. This shows, once again, that these RNA species do not interact with this SR-
protein in the cytoplasm.  
 
Figure 2.17: SRSF3 FRACKING signal along intronic snoRNAs. 
USCS genome browser view for transcript 2410006H16RIK, this transcript contains the snoRNA 
cluster SNORD65 in the intronic regions. The main isoform is presented in black boxes, and black 
lines; ncRNAs are presented as white boxes. 
 
 
To see the global SRSF3 binding pattern with snoRNAs, I plotted the average 
binding coverage of SRSF3 along snoRNAs and the surrounding areas (±1000 nt) 
(Figure 2.18A). The coverage plot for SRSF3 depicted in Figure 2.18A is surprisingly 
different from that observed for SRSF7 (Figure 2.8A). The coverage signals detected 
are low in all fractions, but more significantly, they seem to be lower for the 
chromatin fraction. This is the opposite of what I observed for SRSF7 and it also 
contradicts data presented in the previous chapters (Figure 2.16B).  
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Figure 2.18: Analysis of SRSF3 binding along snoRNAs regions in the different fractions. 
A) Presented here is the average coverage plot for SRSF3 binding on all annotated snoRNAs in 
chromatin (in green), nucleoplasm (in purple) and cytoplasm (in orange), the y-axis values are log2 of 
the binding signal on snoRNA divided by the total signal, total signal is the sum of binding along the 
whole tested region. In the x-axis we have the mature snoRNA sequence from 5’End to 3’End, ±1000 
nt on each side. B) Sum of binding signals of SRSF3 on snoRNA regions for cytoplasm, nucleoplasm 
and chromatin fractions. C) Heatmap of the average binding signal along all annotated snoRNA 
sequences ±1000 nt, each line represents a single snoRNA, values are in log2. 
Contrary to what shown in the coverage plot, the number of peaks on 
snoRNAs for each fraction is higher in signal for the chromatin than in any other 
fraction (Figure 2.18B). To clarify the data shown in the coverage plot, I plotted the 
average binding signals along all snoRNAs as a heatmap (Figure 2.18C). This 
analysis shows that the binding signal along snoRNAs in the cytoplasm is much lower 
than what I detect for the chromatin fraction (Figure 2.18C, left panel). More 
importantly these heatmaps (Figure 2.18C) clearly show the significance of the low
chromatin coverage on snoRNA. The surrounding areas of the snoRNAs are highly 
bound by SRSF3 at levels often close to the areas of the mature snoRNA. Since the 
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coverage signal is relative to the signal of the full area, having a high signal 
surrounding the snoRNAs will significantly lower the coverage along snoRNAs.  
In conclusion, further analysis on SRSF3 binding along snoRNAs, showed 
that SRSF3 strongly binds co-transcriptionally to snoRNAs and that this binding is 
also greatly enriched in the intronic regions surrounding the mature snoRNA. 
 
2.5.2 FRACKING reveals high intronic binding signal for SRSF3 
 
As discussed in session 2.5, the FRACKING data I produced for SRSF3 
showed that this SR-protein, similarly to SRSF7, has high intronic binding levels 
(Figure 2.16A). I decided to further analyze such binding by plotting the average 
profile of cross-linking signal along all exon-intron and intron-exon junctions for all 
bound genes (Figure 2.19A-C). I detected that SRSF3 presents a maximum peak of 
binding signal in the exon area in each of the analyzed fractions, whereas the intronic 
signal is very different between each fraction, as expected. The intron signal proceeds 
from having high levels in the chromatin fraction (Figure 2.19A) to lower, almost 
negligible intronic signal levels in the cytoplasm (Figure 2.19C). The decrease in 
SRSF3 intron binding between fractions accounts for the gradual removal of introns 
from the transcripts operated by splicing.  
From this analysis I could conclude that SRSF3 binding to exons and introns 
is mainly allocated around ±100-150nt from the exon-intron and intron-exon 
junctions, recapitulating its function as a splicing factor. Furthermore, SRSF3 seems 
to be less active than SRSF7 in co-transcriptionally binding near the 5’- and 3’-
splicing junctions of introns, as seen when comparing binding in Figure 2.10A and 
Figure 2.19A. 
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Figure 2.19: Meta-analysis of SRSF3 average binding to exon-intron, intron-exon junctions for 
all transcripts bound in the different fractions. 
A) through C) show SRSF3 binding (number of crosslink sites) averaged for all bound transcripts and 
centered around the exon-intron junction (left) and intron-exon junction (right). The 0 position in the 
plots (black line) represent the indicated 5’ or 3’ splice site; the y-axes represent the number of 
crosslink sites. A) Presents plots for the chromatin fraction (green), B) presents plots for the 
nucleoplasmic fraction (purple), and C) presents plots for the cytoplasmic fraction (orange). 
 
 
2.5.3 Intron-retained isoforms bound by SRSF3 are exported 
 
Because transcript are expected to be fully spliced before being exported to 
the cytoplasm, intron binding signal is expected to be exclusively nuclear. However, I 
identified a subset of transcripts with SRSF3-intronic binding in the cytoplasm. These 
signals are much lower than those detected for the nucleoplasm and chromatin 
fractions (Figure 2.19A-C). Nevertheless, the presence of any cytoplasmic intron 
signal would be surprising if not for the data already presented on SRSF7 (Chapter 
2.4.4, 2.4.5 and 2.4.6). As previously performed for SRSF7, I analyzed the list of all 
transcripts having intronic signal in the cytoplasm, in this analysis I identified 96 
introns that demonstrated binding signal in the cytoplasm (2.20A). This number is 
lower than what was detected for SRSF7 (section 2.4.4). I detected that 77% of the 
introns with SRSF3 binding in the cytoplasm are highly conserved (Figure 2.20B), 
when compared to surrounding introns, for introns I defined high conservation as 
having at least 10% nucleotide identity with vertebrate sequences along the whole 
intron, usually introns present a much lower conservation score, around 2.1% of 
nucleotide identity [93]. More than 50% of the remaining, poorly conserved introns 
showed a very low binding signal (less then 4 crosslink sites along the full intronic 
sequence).  
For my subsequent analyses and experiments, I opted to focus only on the 
introns that were more highly conserved. Further characterization of these data is 
presented in the following section. 
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Figure 2.20: Number and conservation of the intronic sequences with FRACKING signal for 
SRSF3 in the cytoplasm. 
A) Number of introns with SRSF3 binding identified in the different fractions by FRACKING. B) 
Characterization of the conservation for introns that present intronic binding of SRSF3 in the 
cytoplasm (low signal intron are defined as intronic region with a total signal lower than 4 crosslink 
sites). 
 
2.5.4 SRSF3 strongly binds its own transcript and also regulates intron retention 
 
In my data, I could detect that SRSF3 binds to its own transcript in the 
different fractions (Figure 2.21A). Interestingly, SRSF3 has one of the highest levels 
of binding to its own SRSF3 transcript in all fractions (Table 5.2 of the appendix). 
This illustrates the importance for SRSF3 in tightly regulating its own transcript 
throughout all stages of maturation.  
SRSF3 bound with high levels to regions of its own transcript (Figure 2.21A). 
I detected low binding signal for SRSF3 along its exonic sequences, whereas the 
majority of binding signal is located along SRSF3 third intron, in all fractions. 
Importantly, the third intron contains the poison exon for SRSF3 (Figure 2.21A-B, 
exon shown in red). When I examined the third intron of SRSF3 I detected SRSF3-
binding within this area (Figure 2.21B), extending to the full intronic sequence. 
Surprisingly, this intronic binding signal is detected also in the cytoplasm. 
Additionally, this intron is highly conserved in mammalian species (~90%) (UCSC 
Genome Browser [92]), when compared to surrounding introns (Figure 2.21A, gray 
trace). 
 72 
 
Figure 2.21: SRSF3 binding along its own transcript in the different fractions. 
A) Here is presented the USCS genome browser view of SRSF3 binding on its own transcript. The 
main isoform of the SRSF3 transcript is presented as black boxes (exons), and black lines (introns), 
alternative isoforms are presented as white boxes and black lines. Thinner boxes represent untranslated 
regions. The red box represents the SRSF3 poison exon cassette. B) Zoomed view for the 3rd intron of 
SRSF3.  
 
 
Given that splicing occurs before transcript export to the cytoplasm, SRSF3-
intron binding is expected to occur only along the poison exon and not on the two 
introns surrounding the poison exon. These data suggest that the SRSF3 transcript can 
be exported to the cytoplasm, even if it contains the fully unspliced third intron 
(Figure 2.21B). This is in accordance with what I showed in Figure 2.15A (middle 
gel) indicating the presence of the full intron species for SRSF3 in the cytoplasm, 
using cyto-RT-PCR. Importantly, this intron-retained isoform contains a PTC, similar 
to the poison exon and could, therefore, be regulated by the cellular surveillance 
system known as NMD. However, from the data shown in Figure 2.15B, and 
discussed in chapter 2.4.6, I did not detect any significant change in SRSF3 full 
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intron-retained species attributable to CHX treatment. Meanwhile, I did detect a 
strong change in the intensity for the poison exon cassette.  
 
 
Figure 2.22: Examples of SRSF3 binding to highly conserved introns in all fractions. 
A) USCS genome browser view for the binding of SRSF3 on the SRSF7 transcript. B) USCS genome 
browser view for the binding of SRSF3 on the ARGLU1 transcript. A) through B) For each transcript, 
the main isoform is presented as black boxes (exons), and black lines (introns); alternative isoforms 
and are presented as white boxes and black lines. Thinner boxes represent untranslated regions. The red 
box represents the poison exon cassette, when present. 
 
I was able to verify the presence of the poison intron species in the cytoplasm, 
but further experiments will be required to fully elucidate whether this isoform is 
sensitive to NMD.  
The SRSF3 transcript is not the only example of a transcript with high 
conservation rates for retained introns resulting in transcript export to the cytoplasm. 
As previously shown (chapter 2.5.3), I identified 96 transcripts that have intron-bound 
SRSF3 and that are exported to the cytoplasm. Furthermore, 77% of these introns are 
actually highly conserved between mammalian species. Interestingly some of the 
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genes previously discussed for SRSF7 in chapter 2.4.6, also demonstrated strong 
SRSF3 binding along highly conserved introns, namely: ARGLU1 and SRSF7. I 
decided to look at SRSF3 binding along ARGLU1 and SRSF7 transcripts (Figure 
2.22A-B), since I already validated the presence of intron retained isoforms for these 
transcripts in the cytoplasm (chapter 2.4.6 (Figure 2.15A)). I could identify strong 
binding of SRSF3 on these transcripts. SRSF3 binds these transcripts almost 
exclusively along their highly conserved introns (Figure 2.22A-B). 
 For all three transcripts examined herein (SRSF3, SRSF7, and ARGLU1), I 
detect the presence of an intron retaining isoform in the cytoplasm (Figure 2.15A-B) 
for the introns that are strongly bound by SRSF3.  
 
2.6 Polysome analysis reveals the presence of poison introns in the 
monosome and early polysome fractions 
 
Intron-containing mRNA isoforms exported in the cytoplasm could be 
targeted by NMD, due to the presence of PTCs in these isoforms.  As previously 
discussed (chapter 1.3.1), in order for mRNAs to be subjected to NMD, PTC-
containing isoforms need to be exported to the cytoplasm and undergo at least one 
round of translation, as mediated by ribosomes. In Chapters 2.4.5 and 2.4.6, I showed 
that the poison intron-retaining species are detectable in the cytoplasm. To ascertain 
whether these species are associated with ribosomes, I performed polysome 
fractionation on P19 cells using a sucrose gradient method. For a complete 
explanation on polysome fractionations refer to chapter 1.6.2.  
For this experiment, I lysed WT P19 cells and loaded the lysate on a 15-45% 
linear sucrose gradient, and then performed an ultra-centrifugation step on the sample. 
To obtain a profile of ribosomal subunits distribution, I first collected 44 fractions of 
the centrifuged sucrose gradient, with the cell lysate, and measured the absorbance of 
each of the 44 fractions at 254 nm (Figure 2.23A).  
From this analysis, I could clearly distinguish the peaks of the 40S small 
ribosome subunit from the peak of the 60S large ribosomal subunit, as well as the 80S 
peak representing the monosome, and several less pronounced peaks, representing the 
polyribosomes. Cell debris and insoluble material are accumulated in the higher 
sucrose fractions.  
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Figure 2.23: Characterization of polysome fractionation in P19 cells. 
A) Profile of ribosomal subunit distribution for the polysome fractionation. Distributions encompass 44 
sucrose gradient fractions in polysome fractionation. Absorbances for each of the 44 fractions were
measured at 254 nm. Indicated are peaks for the 40S small ribosome subunit, the 60S large ribosomal 
subunit, the 80S peak, representing the monosome; less pronounced peaks represent polyribosomes. B) 
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Gel electrophoresis analysis for total RNA obtained from 11 fractions collected during polysome 
fractionation. Fractions 1-2 were enriched in tRNAs, and fractions 3-10 were enriched in rRNAs. C) 
Western blot analysis on total protein extracts from the polysome fractions, detected by using anti-GFP 
antibody. Top panel: SRSF7-GFP; bottom panel: SRSF3-GFP. Data in A and B were produced with 
the help of Valentina Botti 
 
 
As an additional quality control for the polysome fractionation and to further 
characterize the distribution of ribosomal RNA in all samples, I repeated the 
experiment and collected 11 fractions, from which I then extracted total RNA. I then 
loaded the sample on an agarose gel (Figure 2.23B). As shown in the figure, I 
detected the presence of tRNAs mainly in fraction 1 (low band), whereas rRNAs are 
detected from fractions 3 to 10. Cell debris and insoluble material are present in the 
last fraction. This data and Figure 2.23A verifies that the fractionation was successful 
and with this I could identify fractions 6 to 10 as polysome fractions.  
After isolating the polysome fractions I proceeded to test whether the SRSF7 
and SRSF3 proteins associate with polysomes. To do so, I loaded an equal amount of 
each of the extracted fractions on a SDS-PAGE gel and detected the presence of 
SRSF7 or SRSF3 by western blot. As shown in Figure 2.24C top panel, SRSF7 can be 
detected mostly in the early fractions, but is also present in the deeper polysomal 
fractions, indicating an association with actively translated mRNAs. However SRSF3, 
Figure 2.24C bottom panel, shows only a minor presence in the deeper polysome 
fractions and can be mostly detected in the monosome and early polysome fractions. 
This shows that SRSF3 possibly exhibits a lower association with actively translating 
ribosomes than SRSF7. 
Furthermore, I decided to validate the presence of the poison intron isoforms 
for all the transcripts previously mentioned: SRSF7, SRSF3, ARGLU1 and HNRNPH1 
(chapter 2.4.5 and 2.4.6) and GAPDH as control. The result of RT-PCRs on the 
mRNA extracted from the polysome fractions are shown in Figure 2.24A-D for 
SRSF7, SRSF3, ARGLU1 and HNRNPH1 (RT-PCR for GAPDH can be found in 
Figure 5.2 of the appendix). For all transcripts tested, I detected the poison intron 
isoforms in the early polysomes and I showed that this signal diminishes in the later 
fractions, whereas the GAPDH control showed no change (Figure 5.2 of the 
appendix).  
These data verify that these poison introns are in the cytoplasm and are, 
indeed, associated with the polyribosomes. At present, it remains to be seen as to how 
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the cell regulates these transcripts and how they are degraded and removed from the 
cytoplasmic pool of RNAs. 
 
 
Figure 2.24: RT-PCR analysis for the presence of intron retained species in the polysome 
fractions. 
A) through D) presence of intron retained isoform was hereby tested by RT-PCRs of mRNA samples 
extracted from the last five fractions of the polysome fractionation. A) SRSF7 intron retained isoform 
RT-PCR. B) SRSF3 intron-retained isoform RT-PCR. C) ARGLU1 intron-retained isoform RT-PCR. 
D) HNRNPH1 intron-retained isoform RT-PCR. 
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2.7 Comparison of targets binding for SRSF3 and SRSF7 
 
Previously it was shown that the two SR proteins, SRSF3 and SRSF4, target 
very different sets of transcripts [24]. To test whether the same is true for SRSF3 and 
SRSF7, I compared the set of targets bound in each fraction between the two SR 
proteins (Figure 2.25). From this analysis, I could detect that even if SRSF3 has a 
greater number of targets in each fraction, in the majority of cases it regulates the 
same transcripts as SRSF7. This points toward a high level of redundancy for these 
two SR proteins. However it may also be possible that the two SR proteins function in 
either an antagonistic or synergistic way. 
 
 Figure 2.25 Comparison of targets bound by SRSF3 or SRSF7 in different fractions.  
Comparison of annotated transcripts with significant levels of SRSF3 and SRSF7 binding in chromatin 
(Chr, A)), nucleoplasm (Npl, B)) or cytoplasm (Cyt, C)). 
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3 Discussion  
 
 
3.1 FRACKING: the first high-throughput sequencing method that 
identifies RBP binding dynamics in subcellular compartments 
 
The investigation of RNP targets and their dynamic binding is of primary 
importance due to the extent of regulation operated by RBPs on all cellular functions. 
[2, 3, 6] 
Initial studies on RBPs localization in different cellular compartments were 
mainly based on microscopy techniques, such as shuttling assays [14, 16]. Due to the 
intrinsic limitation of these techniques, no knowledge was acquired regarding the 
RNA-binding capacity and the targets of the RBPs studied. Further studies employed 
cell fractionation in order to investigate the RNA-binding capability of a select 
protein in different sub-cellular compartments [11, 12]. However, these studies were 
limited to cytoplasmic and nuclear fractions and, most importantly, provided no 
information regarding the number and identity of the targets of the selected RBPs.  
Different techniques, namely iCLIP, PAR-CLIP and HITS-CLIP, have 
surfaced in the recent years to better understand the binding locations and targets of 
different RBPs. The above-mentioned techniques are based on UV-crosslinking of 
proteins and RNAs and on the use of stringent IP conditions to specifically select 
RNAs bound exclusively to the protein of interest. However, these techniques are 
limited in their ability to provide static information on RBP targets in the whole cell, 
and cannot detect differences between distinct cell compartments.  
To overcome the limitations found in all previous studies, I developed a new 
technique that combines cell fractionation and iCLIP, which I called FRACKING. 
This new technique allowed me to gather high-resolution, genome-wide data of the 
dynamic binding of two SR-protein family members, SRSF3 and SRSF7, as 
representatives of this class of RBPs. I identified the targets of SRSF3 and SRSF7 
during RNA maturation, which allowed me to discover novel activities for these two 
SR proteins and to identify when and where in the cell they bind to RNA.  
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Future applications of FRACKING will allow for the creation of a RBP 
network specific for each RNA maturation step and create a better understanding of 
the mechanisms underlying RNA-processing events. 
 
3.2 SRSF3 and SRSF7 present different binding patterns in different 
subcellular compartments 
 
Specific	  to	  SRSF3	   Common	  for	  SRSF3	  &	  SRSF7	   Specific	  to	  SRSF7	  
Higher	  number	  of	  targets	  in	  
all	  three	  fractions	  
	   	  
	   Majority	  of	  the	  signal	  detected	  
is	  along	  introns	  
	  
	   High	  levels	  of	  co-­‐
transcriptional	  binding	  	  
	  
	   High	  number	  of	  UTRs	  bound	  
in	  the	  cytoplasm	  
	  
	   	   Higher	  binding	  levels	  for	  
MALAT1	  lncRNA	  in	  the	  
cytoplasm	  
	   High	  levels	  of	  mt-­‐ncRNA	  
bound	  in	  the	  cytoplasm	  
	  
Binds	  to	  mature	  snoRNA	  
sequences	  and	  to	  sequences	  
surrounding	  snoRNA	  
Detected	  binding	  of	  snoRNAs	  
in	  the	  chromatin	  fraction	  
Binding	  located	  along	  the	  
mature	  snoRNA	  sequences	  
	   Higher	  binding	  signal	  detected	  
on	  SRSF3/SRSF7	  transcript	  
	  
Cytoplasmic	  binding	  detected	  
for	  96	  introns	  
High	  conservation	  rates	  in	  
77%	  of	  introns	  identified	  
above	  
Cytoplasmic	  binding	  on	  
intronic	  sequence	  in	  a	  subset	  
of	  transcripts	  
Cytoplasmic	  binding	  detected	  
for	  232	  introns	  
High	  conservations	  rates	  in	  
78%	  of	  introns	  identified	  
above	  
 
Table 3.1: Similarities and differences of FRACKING results for SRSF3 and SRSF7. 
 
 
Previous studies on the genome-wide binding of SR proteins were performed 
only for four SR proteins: SRSF1, SRSF2, SRSF3, SRSF4. These earlier studies 
applied iCLIP and thus focused on the identification of the targets for these SR 
proteins. Unfortunately, this technique only enables data collection from the whole 
cell; ergo, it cannot provide insight into whether binding is taking place on pre-
mRNAs or mature and fully processed mRNAs.  
In my thesis I used FRACKING to detect the RNA binding capacity of SRSF7 
and SRSF3. I could identify that these SR proteins diverge drastically in the number 
of transcripts bound. SRSF3 binds a higher number of targets than SRSF7 in all three 
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fractions (Table 3.1). This points toward a stronger action of SRSF3 in the regulation 
of transcript maturation and export. Further analysis of the data showed that both SR 
proteins present a very dynamic binding profile in the different fractions, presenting 
significant binding differences in different regions for the tested fractions (cytoplasm, 
nucleoplasm and chromatin).  
Here, I presented data that both SRSF3 and SRSF7 mostly bind introns (Table 
3.1), and that such binding is mostly taking place already co-transcriptionally (i.e. 
while the gene is still being transcribed and the RNA is still tethered to the chromatin) 
(Table 3.1). This binding could regulate intron splicing either positively or negatively. 
It was in fact previously shown that SR proteins can bind to introns on intronic 
splicing enhancers or in different regions that negatively effect splicing. Further 
bioinformatic analysis will need to be performed on whole intron sites bound by these 
SR proteins. Then I could determine whether I can identify a prevalence of binding to 
splicing enhancers or even to alternative intronic splice sites that have to be “hidden” 
by SR proteins to avoid aberrant splicing. Here, I show that SRSF3 and SRSF7 
regulation of splicing is taking place for most of their targeted transcripts co-
transcriptionally.  
To further understand how SR proteins are regulating co-transcriptional 
splicing one can imagine using standard RNA-Seq techniques on chromatidic pre-
mRNAs (obtained from my fractionation). This newly obtained sequencing data could 
then be analyzed to calculate the ratio of co-transcriptional splicing for each intron (as 
presented in [83]).  
Correlating co-transcriptional splicing ratios for every single SR-protein 
binding target with the actual extent of SR-protein binding on the target could help 
better understand SR proteins co-transcriptional splicing activity. In this context, 
exons with high SRSF3 or SRSF7 binding ratios should also have high co-
transcriptional splicing for their surrounding introns. Producing RNA-Seq data for the 
three fractions will be a priority in the future. These datasets could be used to 
normalize SRSF3 and SRSF7 binding signals to the levels of the bound transcripts in 
the specific fractions. This would give a more quantitative analysis of SR-protein 
binding, allowing for a better comparison of protein-RNA associations between 
fractions. 
Furthermore, in my FRACKING data I observed a high enrichment in the 
binding of both SR proteins at the 3’UTRs of mRNAs. The effect was less striking 
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but remained present also for 5’UTRs. Binding along UTRs was specific for the 
cytoplasmic fraction (Table 3.1). This cytoplasmic binding along transcript-UTRs 
could be related to either SRSF3 and SRSF7 function as export adapters or, more 
interestingly, to the regulation of translation by SR proteins. In fact, it has been shown 
that SRSF3 can inhibit translation by binding 5’UTRs of a subset of genes, in the 
cytoplasm. Further experiments will be needed to fully elucidate the function for the 
UTR-binding of these SR proteins in the cytoplasm. Future studies could focus on 
mutating the binding sites of UTRs bound by these SR proteins and test whether this 
influences: RNA stability, RNA export or RNA translation. Fully understanding the 
role of SRSF3 and SRSF7-binding at these sites in the cytoplasm would possibly help 
to create a database of UTR targets and the effect of SR proteins on such targets. This 
would help to further understand the mRNA regulation operated by SR proteins. 
 In my FRACKING data analysis, I identified a number of ncRNAs bound by 
SR proteins. Surprisingly, I detected high binding rates for SRSF3 and SRSF7 with 
mt-ncRNAs (Table 3.1). This binding interaction was, almost exclusively, present in 
the cytoplasmic fraction. I detected some mt-rRNA binding signal not only in the 
cytoplasm but also in the nucleoplasm, but only for SRSF3. At this moment, I cannot 
exclude the possibility that this signal originates from mitochondrial contamination of 
the nucleoplasmic fraction.  However, it is important to note that the fractionation 
controls did not show any traces of contamination.  
The presence of mt-RNAs in the cytoplasmic fraction can be easily explained 
since, in my protocol, I do not selectively remove mitochondria from the cytoplasm. It 
is feasible to expect lysed mitochondria to remain in the cytoplasmic fraction. 
Unexpectedly, I detected SR-protein binding to mt-ncRNAs. This might be the first 
time that such binding has been reported to date. Given our knowledge regarding SR-
protein cellular localization, SR proteins are not expected to localize to the 
mitochondria. It is thought that SR proteins localize only briefly to the cytoplasm. 
However, with the present data, I cannot exclude the possibility that SR-protein, even 
if just briefly, travel into mitochondria.  
To verify whether SR proteins localize to mitochondria, as indicated from my 
experiments, it will be necessary to further validate the presence of SR proteins in the 
mitochondria using microscopy and fractionation techniques. I would have to perform 
such analysis with or without UV-crosslinking to ensure that the UV-crosslinking 
operated in FRACKING is not affecting the stability of the mitochondria and so 
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giving a false positive signal. Using fluorescence microscopy I obtained preliminary 
data, showing that mitochondria change morphology and can fuse together when 
treated with UV (at the same levels as in FRACKING) when the P19 cells are left at 
37oC for 15 minutes (data not shown). However, throughout my FRACKING 
protocol, I maintain the cells at 4oC at all times, and the cells are kept on ice 
throughout the UV-crosslinking procedure. Further experimentation will be needed to 
fully understand this preliminary data.  
Binding of SR proteins on mt-ncRNAs could indicate a previously un-
described function of SR proteins in the maturation of mitochondrial-ncRNAs. mt-
ncRNAs need to be processed to be functional and stable in the cell, and the processes 
that lead to production of mature mt-ncRNAs are still not well described. It is possible 
that SR proteins, due to their ability to regulate RNA processing and stability for all 
classes of RNAs, could also be involved in mediating stability or biogenesis of these 
mt-ncRNAs. Another interesting hypothesis is that SR proteins bind these mt-
ncRNAs to translocate some of them to the cytoplasm to be degraded. Further 
analysis will be required to fully elucidate these surprising results. 
 In conclusion, FRACKING of SRSF3 and SRSF7 allowed me to identify 
specific subcellular interactions and identify novel functions for these two important 
SR proteins. This information would have been impossible to gather using current, 
standard sequencing methods, since in these methods it is impossible to evaluate the 
contribution of each individual fraction. Here, I describe the first dynamic evaluation 
of RNA binding of RBPs in a transcriptome-wide context. I could show, for the first 
time, the degree to which SRSF3 and SRSF7 co-transcriptionally bind RNA and that 
they often travel to the cytoplasm with their target RNAs.  
 
3.3 SRSF7 possibly mediates MALAT1 lncRNA export to the 
cytoplasm 
 
In my FRACKING data for SRSF7, I surprisingly detected cytoplasmic-
binding of SRSF7 with the long non-coding RNA MALAT1 (Table 3.1). This is quite 
unexpected since most experiments localize MALAT1 exclusively to the nucleus, 
specifically to the nuclear speckles [47]. Furthermore, MALAT1 is thought to have a 
nuclear retention signal in its sequence.  In the last year, many researchers have 
 84 
shown the presence of this lncRNA in polyribosomes and in the cytoplasm [89, 90, 
95, 96]. My FRACKING data, not only corroborates the findings that MALAT1 can 
shuttle to the cytoplasm, but that it might do so by interacting with SRSF7. I showed 
that SRSF7 binds strongly to MALAT1 in the cytoplasm. Similarly, a recent iCLIP 
analysis for NXF1 (data not shown, unpublished data from Michaela Müller-Mcnicoll 
and Valentina Botti) shows that NXF1 binds to MALAT1. As mentioned previously, 
SRSF7 can interact directly with NXF1 to mediate RNA export [11, 12]. Since I 
detected SRSF7 cytoplasmic-binding for MALAT1, this SR-protein could mediate the 
recruitment of NXF1 to MALAT1. This would lead to a small portion of this lncRNA 
being exported to the cytoplasm where it has been shown to associate with active 
polysomes. However, the ability of MALAT1 to be translated has yet to be shown. 
Nevertheless, the presence of MALAT1 in the cytoplasm has to be considered as a rare 
event, as it has not been extensively described in the literature. This shows once again 
the ability of FRACKING to identify rare, but biologically important RNA-protein 
interactions in different compartments of the cell. 
 
3.4 SR proteins bind snoRNAs in the chromatin fraction  
 
FRACKING data for both SRSF7 and SRSF3 showed a high enrichment of 
binding signal for a particular class of nuclear ncRNA, the small nucleolar RNAs 
(snoRNAs) (Table 3.1). This signal was almost exclusively found in the nucleus 
(nucleoplasmic and chromatin fractions). It was already shown by a previous iCLIP 
study that SRSF3 could bind snoRNAs in the cell [24]. Nevertheless, the authors 
could not distinguish whether such binding was happening in the nucleoplasm or in 
the chromatin. In my data, I observed that the SRSF3 binding on snoRNAs is mainly 
on chromatin, and that the same behavior can be shown for SRSF7. Indeed, this data 
shows that SR proteins are possibly interacting with pre-snoRNAs. From the 
FRACKING data, I could identify two different hypotheses to explain the chromatin-
binding capacity of SR proteins:  
 
1) SR proteins bind pre-snoRNA, co-transcriptionally and aid in their 
maturation. 
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2) SR proteins stabilize and protect mature snoRNAs that are located in the 
chromatin. 
3) SR proteins associate with snoRNAs present in the chromatin due to rRNA 
processing. 
 
  Due to the nature of the data and analysis, I cannot fully exclude the 
possibility that part of the binding detected is happening on mature snoRNAs rather 
than pre-snoRNAs. Lastly, further analysis of the FRACKING binding data for 
snoRNAs showed striking differences in the RNA-binding behaviors between SRSF3 
and SRSF7.  
In the SRSF7 chromatin FRACKING data, I detected the majority of protein-
RNA binding along the mature sequence of snoRNAs with only minor signal in the 
surrounding areas. Most of this binding exhibited a sharp peak located near the 5’-end 
of the snoRNAs, possibly indicating that SRSF7 binds to the 5’end of pre-snoRNAs 
to guide their maturation or stabilize these RNAs during their maturation process. 
From this data, I can show, that SRSF7 binds snoRNAs, preferentially along their 
mature sequence in the chromatin fraction.  
As seen for SRSF7 FRACKING data, I observed that the majority of SRSF3-
binding to snoRNAs also takes place in the chromatin fraction. However, the resulting 
binding signal for SRSF3 was comparably different from that of SRSF7.  While the 
majority of protein-RNA binding for SRSF3 occurs along the mature snoRNA 
sequences, a very significant portion of SRSF3 binds along the intronic regions 
surrounding the mature sequence of the snoRNAs. These data suggests the fact that 
SRSF3 might bind mostly pre-snoRNAs and that its binding takes place in the 
intronic flanking regions of the snoRNA. In this way SRSF3 can either stabilize pre-
snoRNA during its biogenesis or actively guide its maturation.  
In contrast, SRSF7 may bind mostly to mature snoRNAs, thereby possibly 
aiding in stabilization of mature snoRNAs. It might also be possible that SRSF7 
binding is taking place on pre-snoRNAs. However, SRSF7 seems to perform a 
different function from SRSF3 in its interaction with snoRNAs.  
SRSF7 seems to stabilize pre-snoRNAs, during their co-transcriptional 
processing, by binding to their mature sequence area. SRSF3 may, instead, help pre-
snoRNA biogenesis by guiding the degradation of the regions flanking the mature 
snoRNA sequence.  
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With FRACKING, I could identify a novel interaction between SR proteins 
and snoRNAs on the chromatin, raising the possibility that the majority of this 
binding occurs on pre-snoRNAs. Furthermore, I showed that SRSF3 and SRSF7 act 
differently on these snoRNAs. SRSF7 binds almost exclusively to the mature 
snoRNAs sequence. On the other hand, SRSF3 binds strongly also to the regions 
surrounding the mature snoRNAs sequence. This indicates a differential regulation of 
snoRNAs by distinct SR proteins. 
 
3.5 SRSF3 and SRSF7 associate with retained introns in the 
cytoplasm 
 
Recent publications have shown that splicing takes place mainly co-
transcriptionally [1]. Furthermore, all introns are thought to be excised from mRNAs 
before the mRNAs are exported in the cytoplasm [91], since it is important for the cell 
to avoid translating mRNAs that will produce unstable proteins. It has been shown, in 
humans, that roughly 96% of introns are removed from the nucleoplasmic mRNAs. 
However, it has also been shown that co-transcriptional splicing is lower in mouse 
than what observed in other species analyzed [1, 97]. It is still not known if this lower 
co-transcriptional efficiency has repercussions for post-transcriptional splicing in 
mouse.  
Nevertheless, these data sets are produced by standard RNA-seq, which can 
under-represent unstable transcript isoforms. For example, low-level isoforms, such 
as rapidly degraded transcripts, are rarely identified in RNA-seq studies for steady 
state mRNAs. By using FRACKING, I can pull-down and positively select very rare 
transcripts if they are strongly bound by the protein tested.  
It has been shown in most iCLIP papers how iCLIP binding signal does not 
correlate with expression levels [24, 76].  
In my FRACKING data, I easily identify cytoplasmic transcripts that present 
intron retention and that are strongly bound by SRSF3 and/or SRSF7.  I further 
detected, 96 and 232 unspliced cytoplasmic introns that are bound by SRSF3 and 
SRSF7, respectively (Table 3.1).  
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Interestingly for both proteins, roughly 78% of the detected introns with 
cytoplasmic signal had high sequence conservation between mammals, which is 
surprising considering the usual low conservation levels for introns. 
To further characterize such binding, I selected four different transcripts that 
possessed highly conserved introns and binding for one or both SR proteins tested: 
ARGLU1, HNRNPH1, SRSF3 and SRSF7. Surprisingly, these intron-retained species 
contain premature stop codons (PTC) within their retained intron. For this reason, I 
designated these introns as “poison introns”.  
PTCs can often be found within alternatively spliced exons that regulate, with 
their inclusion or exclusion, the levels of transcripts. In fact, PTC containing isoforms 
are usually unstable and are degraded in the cytoplasm by nonsense mediated decay 
(NMD) or nonsense mediated translation repression (NMTR). Furthermore, all SR 
proteins regulate the levels of their own transcripts by mediating the splicing of PTC 
containing isoforms for their own transcripts.  
Studies have shown that all SR proteins encode an alternative PTC containing 
exon (named poison exon) for which its inclusion is usually regulated by the SR-
protein itself [44]. I could validate previous findings with my experiments.  
Interestingly, this binding was not exclusively present on the poison exon, but 
extended to the full intron abutting the poison exon. Furthermore, I detected binding 
to such introns also in the cytoplasm. This points toward the possibility that SR 
proteins have a secondary ability in regulating their own transcript levels by guiding 
the production of transcripts containing a retained-poison intron, which will be 
degraded in the cytoplasm. This would allow the SR proteins to control the stability of 
their own transcript through different mechanisms.  
Furthermore, I detected that the SRSF7 protein could bind the transcript of 
SRSF3 and vice versa, SRSF3 could bind the SRSF7 transcript. Importantly, this 
RNA binding occurred along the poison intron regions. This indicates a possible 
cross-regulation for SRSF3 and SRSF7 upon each others' transcripts. It is possible 
that SRSF7 regulates alternative splicing of SRSF3 transcripts and similarly SRSF3 
could regulate SRSF7 alternative splicing. 
Furthermore, I also detected cytoplasmic binding of SRSF3 and/or SRSF7 on 
the other two tested transcripts: (HNRNPH1 and ARGLU1). In both cases this protein-
RNA binding occurred mostly along a highly conserved intron. This raises the 
possibility that the two SR proteins tested can regulate the inclusion of such poison 
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introns and, therefore, regulate the export of transcripts produced by these splicing 
events.  
Importantly, the ARGLU1 transcript encodes for an uncharacterized protein. A 
further look at the ARGLU1 protein showed that it contains a domain with a high 
number of SR-repeats, as already found in SR and SR-like proteins. Furthermore, the 
only published data on ARGLU1 connects this protein with the proliferation of breast 
cancer [98] as seen for SRSF3 [99]. These findings suggest that ARGLU1 is another 
potential SR-like protein. It will be interesting to test whether ARGLU1 can interact 
with SRSF3 or SRSF7 in the cell. Studying this interaction is currently challenging 
since commercially available antibodies showed to be unspecific. This will be 
circumvented in future experiments by using a GFP-tagged ARGLU1. 
In my analysis, I was able to validate, independently from UV-crosslinking 
and immunoprecipitation methods, that the poison intron isoforms are present in the 
cytoplasm. However, when I tested their sensitivity to NMD inhibition, I did not 
detect any significant effect on these isoforms.  This result could be indicative of 
several different possibilities:  
 
1) The method I used to inhibit NMD was indirect, in that it depended on the 
translation inhibitor (cycloheximide) to which most, but not all NMD 
targets seem to be sensitive [100]. Using a more direct means of NMD 
inhibition could yield different results.  
 
2) These transcription isoforms are not degraded, but instead, are quickly 
reimported back into the nucleus where they can either be properly spliced 
or degraded.  
 
3) These isoforms are not regulated by NMD, but by another degradation 
mechanism. Presently, the knowledge on other cytoplasmic surveillance 
mechanisms is quite abysmal; these isoforms could be regulated by 
NMTR, which is a poorly studied surveillance mechanism that seems to 
target NMD resistant isoforms [54, 58]. 
 
Further experiments will inform as to the fate of these poison intron isoforms.  
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In my study, I also addressed the question as to whether or not these poison introns 
proceed onward to polysomes. These introns would need to associate with polysomes 
for the NMD mechanism, or other cytoplasmic surveillance mechanism, to detect 
them as targets for degradation. To study this hypothesis, I performed polysome 
fractionation and indeed observed that poison intron isoforms are present in 
polysomes, albeit at lower levels than constitutively spliced isoforms, for all four 
genes tested. Interestingly these poison intron isoforms appear to be mostly located in 
the early fractions of polysomes as well as in the monosome fraction. Once again, this 
further confirms that these poison introns are localized to the cytoplasm. 
Furthermore, the low levels of poison introns detected in the polysome 
fractions suggest that these isoforms are not fully translated. Further experiments are 
needed to reveal the mechanisms regulating these isoforms, and whether they can 
produce any peptides. If such intron isoforms were translated, it would be needed to 
consider whether their peptides are functional or if they are then degraded. 
My data challenges current textbook knowledge and extends our 
understanding of mRNA splicing and subsequent RNA export from the nucleus. Here, 
I detected and validated the cytoplasmic localization of mRNA isoforms that retained 
incompletely spliced introns. Originally, it was believed that these isoforms were 
always retained in the nucleus. My data strengthens information gained by recent 
reports that detected cytoplasmic reads for intron-retained RNA species [101, 102]. 
To date, no satisfactory explanation for the biological export mechanisms for 
these isoforms has been described. Not only have I confirmed that a portion of intron 
retained isoforms endure to be exported to the cytoplasm, but that their export is 
correlated by extensive SR-protein associations with these transcripts. As of yet, it is 
not clear what mechanism regulates the degradation of these transcripts. Currently, 
these transcripts are not expected to be stable, since they are likely to produce 
unstable proteins and peptides. From my experiments, these isoforms appear to be 
insensitive to NMD, which prompts me to think that these isoforms might be 
regulated by a secondary surveillance mechanism such as NMTR. 
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3.6 Concluding remarks 
 
To date, my study provides the first ever transcriptome-wide description of 
RBP-binding RNA through RNA maturation. I showed, in vivo, that SR proteins can 
dynamically bind RNAs, initiating co-transcriptionally, and that this interaction can 
be maintained through RNA maturation. I identified SRSF3 and SRSF7 binding to 
RNAs in the cytoplasm as well as in the nucleus (Table 3.1). These findings further 
strengthen the idea that SR proteins are master regulators throughout the life of RNA. 
In order to assess transcripts during their maturation, I developed a new technique 
called FRACKING. This technique combines stringent cell fractionation with the 
abilities of iCLIP to detect specific RNA binding sites and targets for the selected 
protein of interest.  
By employing FRACKING on SRSF3 and SRSF7, I was able to show that SR 
proteins have distinct RNA binding associations in different subcellular fractions, and 
observed that both SR proteins can bind their target co-transcriptionally. I found that 
both SR proteins present a high level of binding for the 3’UTRs in cytoplasmic 
RNAs, thereby recapitulating their activity as export adapters. To further this point, 
these SR proteins also guide NXF1 to bind mRNA and mediate mRNA export to the 
cytoplasm.  
I reported here, that SRSF3 and SRSF7 associate with snoRNAs in the 
chromatin. It is possible that SRSF3 and SRSF7 associate with pre-snoRNAs co-
transcriptionally and this binding is significantly different between the two SR 
proteins.  
These data give more insight into the varying functions and activities of 
different SR proteins. I also detected high levels of SR-protein binding to introns in 
the chromatin and that these interactions are greatly diminished in the other fractions, 
recapitulating the activity operated by SR proteins in splicing. Lastly, I identified a 
subset of genes with high cytoplasmic intronic binding in highly conserved introns 
through FRACKING, thereby identifying novel alternative splicing events, alternative 
termination events, and cytoplasmic intron retention events.  
Lastly, with further experimentation I verified the cytoplasmic presence of a 
number of intron-retained isoforms that were bound by SR proteins and exposed the 
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association of these isoforms with polysomes. Further studies will be needed to 
characterize the surveillance mechanism regulating these intron-retained species.  
Finally these data show that SR proteins could be involved in mediating the 
retention of unspliced introns in RNA transcripts. Furthermore, these SR proteins 
possibly play a role in exporting these intron-retained isoforms from the nucleus to 
the cytoplasm. In spite of the fact that there are still many questions regarding the 
roles played by SR proteins in the cell, the development and application of my 
FRACKING technique has provided insights into rare and specific SR proteins 
interactions with RNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
4 Materials and Methods 
 
4.1 Cell lines 
 
The cell lines used in this study were WT P19 cells and two P19 cell lines 
carrying a stable integrated copy of a BAC-transgene, SRSF7 and SRSF3, that was 
GFP tagged and expressed under the control of the endogenous promoter. Michaela 
Muller-McNicoll kindly provided these cell lines. 
 
4.2 Growth Conditions 
 
P19 cells were grown in Dulbecco’s Modified Eagle Medium, (4.5g/L of D-
Glucose and 110 mg/L of Sodium Pyruvate) (Life Technologies). The medium was 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS, Life 
Technologies) and 100 Units/ml (U/ml) Penicillin and 100 µg/ml Streptomycin (Pen-
Strep, Life Technologies). Additionally, for BAC containing cell lines, 500 µg/ml of 
geneticin (Life Technologies) was added to the media. The cells were grown, until 
needed, on cell culture dishes coated with 0.1% of gelatin (Life Technologies), in a 
cell culture incubator with 5% CO2 and at 37°C. 
 
4.3 RNA isolation 
 
For RNA isolation, one 10 cm plate with 90% cell confluency (approximately 
8 x 106 cells) was incubated at room temperature for 3 min with 2ml of 0.05% 
Trypsin-EDTA (Life Technologies). After the incubation, 4 ml of DMEM medium 
was added to the cells. The cells were centrifuged at 1,000 rpm for 5 min at room 
temperature and the supernatant was discarded. The cell pellet was washed with 5 ml 
of 1X PBS and then centrifuged once again at 1,000 rpm for 5 min at room 
temperature. The cell pellet was resuspended in 1 ml of TRIzol reagent (Life 
Technologies) and the cells were lysed by pipetting up and down gently. The samples 
were at this point stored at -80°C overnight, to aid in the completion of the cell lysis.  
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Subsequently, the samples were thawed on ice and 200 µl of chloroform was 
added. The samples were mixed and centrifuged at 10,000 rpm for 15 min at 4°C.  
After the centrifugation the aqueous upper phase was carefully transferred to a 
fresh tube and the RNA was precipitated with 500 µl isopropanol by mixing, followed 
by 30 min incubation on ice and centrifugation at 14,000 rpm for 30 min at 4°C. The 
supernatant was removed and 400 µl of 70% Ethanol was added to each sample. 
Afterwards the samples were centrifuged at 14,000 rpm for 5 min at 4°C. The 
supernatant was then removed and the samples were dried at room temperature for 10 
min. The samples were resuspended in 80 µl of nuclease free water. To remove 
contaminating genomic DNA, the samples were DNAse treated with 10 µl of 10x 
DNAse buffer and 10 µl of TURBO DNAse I at 2 U/µl (Life technologies) for 30 min 
at 37°C. Subsequently, the RNA was precipitated with 10 µl of NH4Ac and 275 µl of 
100% Ethanol by mixing, followed by an overnight incubation at -80°C and 
centrifugation at 14,000 rpm for 30 min at 4°C. The supernatant was removed, the 
pellets were then washed once with 400 µl of 70% Ethanol and centrifuged at 14,000 
rpm for 5 min at 4°C. The supernatant was removed and the pellets were dried at 
room temperature for 5 min. The pellets were then resuspended in 40-80 µl of 
nuclease-free water. Here, the volume of water added depended on the final size of 
the pellet. The RNA concentration of the samples was then measured using the 
Nanodrop2000 machine (Thermo scientific). 
 
4.4 P19 subcellular fractionation  
 
 Cells were grown until they reached 90% confluency in a 15 cm plate. Then the 
cell plates were placed on ice and the growth medium was removed. The cells were 
carefully washed twice with 10 ml of 1X ice cold PBS. A final 10 ml of ice cold PBS 
was added to the cells.  
 At this point the cells were UV crosslinked using a Spectrolinker XL-1500 
(Spectronics corporation) with a wavelength of 254 nm and energy of 100mJ/cm2. 
The UV-crosslinking was done only if the sample was to be used for iCLIP. The cells 
were then detached from the plate by scraping with a cell scraper. The detached cells 
(in PBS) were transferred to a 15 ml falcon tube and then centrifuged at 1000 rpm for 
5 minutes at 4°C. At this point the supernatant was removed and the pellet was gently 
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resuspended in 2 ml Hypotonic buffer (10 mM Tris-HCl pH 7.5, 10 mM KCl, 1.5 mM 
MgCl2, 0.5 mM DTT; supplemented with 1X Protease inhibitor cocktail (Roche)). 
The samples were separated into two fresh 1.5 eppendorf with 1 ml each that were 
processed in parallel. The samples were incubated on ice for 15 minutes and 
centrifuged at 2,000 rpm for 10 minutes at 4°C. The supernatant was discarded. Cell 
pellets were resuspended in 1 ml of Lysis buffer 0.3 (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 2 mM MgCl2, 0.3% NP-40 (v/v); supplemented with 1X Protease inhibitor 
cocktail (Roche)) and incubated on ice for 10 minutes before centrifugation at 3,000 
rpm for 10 minutes at 4°C. The supernatant was saved in a clean eppendorf tube (this 
is the cytoplasmic fraction).  
 The pellet was resuspended with 1 ml Lysis buffer 0.5 (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 2 mM MgCl2, 0.5% NP-40 (v/v); supplemented with 1X Protease 
inhibitor cocktail (Roche)) and incubated on ice for 10 min before being centrifuged 
at 3,000 rpm for 10 minutes at 4°C. The supernatant was discarded and the pellet 
(containing the nuclei) was resuspended in 100 µl of Buffer 1 (50% glycerol (v/v), 20 
mM Tris-HCl pH7.9, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT), followed by 900 
µl of Buffer 2A (20 mM HEPES pH 7.6, 300 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 
7.5 mM MgCl2, 1M Urea, 1% NP-40 (v/v)). The samples were vortexed for 5 sec and 
incubated on ice for 10 minutes.  
 The chromatin was sedimented at 10,000 rpm for 5 minutes at 4°C. The 
supernatant was transferred to a clean 1.5 ml eppendoprf (nucleoplasmic fraction). 
Then 100 µl of Buffer 1 was added to the samples with 900µl of Buffer 2B (20 mM 
HEPES pH 7.6, 300 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 7.5 mM MgCl2, 1M 
Urea, 1.5% NP-40 (v/v)). Samples were vortexed for 5 sec and incubated on ice for 
10 minutes. The chromatin was sedimented at 10,000 rpm for 5 minutes at 4°C. The 
supernatant was trashed and the samples were washed twice by adding 600 µl of 
Buffer 2A. Finally, the chromatin was sedimented at 10,000 rpm for 5 min at 40C. 
The sample (containing the purified chromatin fraction) was resuspended in 1 ml of 
Buffer 3 (10 mM Tris-HCl pH 7.5, 500 mM NaCl, 10 mM MgCl2).  
 The chromatin and nucleoplasm fractions were sonicated with a Branson digital 
sonifier (BRANSON) at 30% amplitude, for 30 sec. total (10 sec. ON and 20 sec. 
OFF). Then all three fractions were separately centrifuged at 10,000 rpm for 5 
minutes. The supernatant were saved to a clean 1.5 ml eppendorf tubes. Fractionation 
was tested with fraction specific markers on WB using 1/100th of each fraction. If the 
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preparation was pure and no cross-contamination was detected by the markers, the 
samples were subjected to iCLIP as shown in chapter 4.7, for FRACKING samples. If 
the samples were extracted for the RNA they were subjected to the protocol in chapter 
4.3. 
 
4.5 Protein sample isolation and quantification 
 
Cells were plated on a 10 cm plate and grown to 90 % confluency (approx. 
8x106 cells). The medium was aspirated and the cells were washed twice with ice-
cold 1X PBS before 5 ml NET-2 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 
mM MgCl2, 0.05% NP-40 (v/v); supplemented with 1X Protease inhibitor cocktail 
(Roche)) was added to the cells. The lysate was sonicated (with a Branson Digital 
Sonifier) for 30s at an amplitude of 30 % and centrifuged for 5 min at 14,000 rpm at 
4°C, to pellet cell debris.  
The supernatant was collected and the protein concentration was determined 
by Bradford assay. Protein extracts were diluted 1:1,000 to 1:10,000 in 800 µl of 
ddH2O and a standard curve with 10, 5, 2.5 and 1.25 µg/ml BSA was prepared. 
Finally 200 µl of Bradford reagent (Bio-Rad Protein Assay Dye Reagent Concentrate) 
was added, mixed and then incubated for 5 min at RT. The absorbance was measured 
at 595 nm. 
 
4.6 SDS-PAGE and western blot analysis 
 
For SDS-PAGE, 1 to 20 µg of total protein samples was combined with 
Laemmli loading buffer (Bio-Rad) and heated to 95°C for 5 min. The samples were 
loaded on a pre-casted NuPAGE 4-12 % Bis-Tris gel (Invitrogen) and run at 200 V, 
180 mA for 45 min in NuPAGE MOPS SDS running buffer (Invitrogen) using the 
Invitrogen X Cell Sure Lock system. After electrophoresis, the proteins were 
transferred to a Whatman nitrocellulose membrane using a semidry, horizontal 
transfer system (Ellard Instruments) for 2 h at 175 mA (Western Transfer buffer: 48 
mM Tris base, 37 mM glycine, 0.037 % (w/v) SDS, 20% methanol, pH 7.0-8.8).  
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The quality of the transfer was evaluated by staining the membrane with 
Ponceau S staining solution (0.1 % (w/v) Ponceau S (Sigma) in 5 % (v/v) acetic acid). 
After destaining in PBST (0.1 % (v/v) Tween 20 in PBS), the membrane was blocked 
with 3 % BSA in PBST for at least 1h min at RT or overnight (O/N) at 4°C. After 
blocking, the membrane was washed briefly in PBST, twice. The membrane was 
incubated with the primary antibody for 1h with shaking at RT or O/N at 4°C (for a 
list of antibodies and their dilutions see table 4.1). Following the antibody incubation, 
the membrane was washed 3 x 5 min in PBST. 
The secondary antibody was diluted in 4 ml of 3% BSA in PBST for 45 min 
while shaking at RT. The membrane was again washed in PBST, before addition of 
the chemiluminescent reagent (ECL, GE Healthcare or SuperSignal West Femto, 
Roche). The chemiluminescent signal was detected by film (Hyperfilm, GE 
Healthcare) or camera (Chemi-smart, Vilber Lourmat). 
 
Company Antibody IgG Dilution (in TBST 3% 
BSA) 
Millipore αEGFP Mouse 1:5,000 
Santa Cruz 
Biotechnology 
αGAPDH Rabbit 1:1,000 
Santa Cruz 
Biotechnology 
 α9G8 (SRSF7) Rabbit 1:1,000 
Gift Karla Neugebauer α7B4 (SRSF3) Mouse 1:1,000 
Santa Cruz 
Biotechnology 
αTAP (NXF1) Goat 1:750 
AbCam αHistone H3 Rabbit 1:10,000 
Santa Cruz 
Biotechnology 
αRNA Pol II Rabbit 1:2,000 
GE	  Health	  care	   α-rabbit-HRP 	   Donkey	   1:8,000	  
Sigma	   α-goat-HRP	   Donkey	   1:8,000	  
Sigma	   α-mouse-HRP	   Goat	   1:10,000	  
 
Table 4.1: List of antibodies used in this study. 
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4.7 iCLIP 
 
Crosslinked samples for cytoplasm, nucleoplasm and chromatin were obtained 
as described in chapter 4.4 and then subjected to the iCLIP protocol as described in 
[77]. In this way, FRACKING data was obtained.  
 
4.8 Bioinformatic analysis of sequencing data 
 
The FRACKING data was uploaded to the bioinformatic tool known as 
iCOUNT (http://icount.fri.uni-lj.si/) and then analyzed using default iCOUNT 
options. All replicates were pooled to allow the definition of the position and score of 
the significant peaks. 
Figure 2.10A-C and 2.19A-C show results after obtained by plotting the 
iCOUNT data in the statistical program R. The average binding profile obtained from 
iCOUNT were centered on the 5’ and 3’ splicing sites.  
Intron analysis was performed by intersecting the peak locations, obtained 
from iCOUNT for the cytoplasmic fraction, with the genomic coordinates for introns. 
The list so obtained, contained all the introns with cytoplasmic binding of either 
protein. Only introns with more than three crosslink sites were considered for 
subsequent analyses. Introns from the resulting list were manually analyzed for 
conservation scores in the UCSC genome browser [92].  
Coverage plots and the heatmap of Figure 2.8A-B and 2.18A&C were 
obtained by intersecting significant binding sites with the snoRNA genomic position 
(±500 or 1,000 nt) and then plotted using ngs.plot (https://github.com/shenlab-
sinai/ngsplot) [103]. To obtain the shown coverage plots, the peak signal for each 
nucleotide position along single snoRNAs sequences (±500 or 1,000 nt) is normalized 
by being divided for the total signal of the tested area. The number obtained at each 
site for each snoRNA is then average with the values obtained for all other snoRNAs 
and then it is transformed in log2 scale. Finally the final log2 signal is plotted along the 
snoRNA sequence (±500 or 1,000 nt). In the heatmap plots the binding signals are 
represented as colors, where white is the lowest and red is the highest. The plot is 
obtained by calculating the log2 values for the binding signal at every single 
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nucleotide along the snoRNA sequences (± 500 or 1,000 nt), and plotting each 
snoRNA sequence as a single row. 
 
 
4.9 Reverse transcription 
 
Isolated total RNA was converted to cDNA with Superscript III Reverse 
Transcriptase (Invitrogen). 1 µg of RNA was diluted in 11µl of nuclease free water, 
1µl dNTP mix (Bioline), 0.5 µl random Hexamers (Roche), 0.5 µl oligodT18 
(SIGMA--‐Aldrich) and then incubated for 5min at 65°C. After 1 min on ice 4µl of 
5xFirst Strand buffer (Invitrogen), 1 µl 0.1 M DTT (Invitrogen), 0.5 µl RNaseOUT™ 
Recombinant Ribonuclease Inhibitor (Invitrogen) and 1 µl Superscript III RT at 200 
U/µl (Invitrogen). The reaction was incubated for 1h at 50°C and heat--‐ inactivated 
at 70°C for 15min. The resulting cDNA was stored at --‐20°C until usage.  
4.10 PCR 
 
Conventional PCR was used for the analysis of cDNA. The reaction was 
carried out in a total volume of 25 µl which contained 5 µl 5x Phusion™ HF Buffer 
(Biozyme), 1 µl 10  mM dNTP mix (Invitrogen), 0.5 µl each of 10 µM forward and 
reverse primer, 1-2 µl of cDNA, 0.2 µl of Phusion polymerase (Biozyme) and ddH2O 
to fill up the reaction. The material was amplified in a Eppendorf PCR cycler 
following the manufacturer instructions. 
 
4.11 Polysome fractionation 
 
For polysome fractionation, the 10X gradient buffer (GB) was prepared by 
mixing 100 mM HEPES-KOH (pH 7.2), 1500 mM KCl and 50 mM MgCl2. A 100 ml 
50% Sucrose solution was prepared by combining 50 ml of 1X GB with 50 mg of 
sucrose, this solution was complemented with 1x of protease inhibitor cocktail 
(Roche). Subsequently the gradients were prepared as shown in Table 4.2. 
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Sucrose (%) 1XGB (ml) 50% Sucrose (ml) 
15 10.5 4.5 
22.5 8.25 6.75 
30 6.0 9.0 
37.5 3.75 11.25 
45 1.5 13.5 
  
Table 4.2: Reagents used in the preparation of sucrose gradients. 
 
The prepared sucrose solutions were then cooled for at least 1h. Afterwards, 
Beckman centrifuge tubes were placed in a stable holder (to avoid vibration that 
would mix the gradient), and 2 ml of the 45% sucrose solution were carefully pipetted 
at the bottom of the tube. Subsequently each sucrose solution was slowly overlaid 
with the preceding cushion, to avoid mixing the solutions. The gradients were then 
incubated in at 4°C overnight in the cold room.  
Cells grown to 90% confluency in 15 cm plates were treated with 100 µg/ml 
of CHX for 30 min. Afterwards, the cells were incubated at room temperature for 3 
min with 4 ml of 0.05% Trypsin-EDTA to detach the cells. After the incubation, 8 ml 
of DMEM medium was added to the cells, to inhibit Trypsin. The detached cells were 
transferred to a 15 ml Falcon tube and centrifuged at 1,000 rpm for 5 min at room 
temperature. Afterwards, the cell pellet was washed once with 1X PBS and 
centrifuged again at 1,000 rpm for 5 min at room temperature. The supernatant was 
discarded and cells were resuspended in 1X Lysis buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 2 mM MgCl2, 0.3% NP-40 (v/v); supplemented with 1X Protease 
inhibitor cocktail (Roche)) and incubated for 10 min at 4°C. The cell lysate was 
collected by centrifuging the samples at 14,000 rpm for 5 min at 4°C and transferring 
the supernatant (cell lysate) to a clean tube.  
Afterwards, 800 µl of cell lysate was carefully added on top of the sucrose 
gradients. The tubes were then placed in the rotor buckets, which were tightly sealed 
and carefully inserted into the Beckman rotor (SW41Ti). The samples were then 
centrifuged at 40,000 rpm for 2h at 4°C. Afterwards, the samples were moved to the 
cold room and 1ml from the top of each gradient was transferred to its own 1.5 ml 
eppendorf tube. In this way, 11 fractions were isolated and stored at -20°C. Separately 
44 fractions were isolated to measure the absorbance (Abs) curve for the 
fractionation, 250 µl were taken instead of 1ml to collect 4 times more fractions. To 
test the protein content of the polysome fractions on SDS-PAGE and western blot, 50 
µl were taken from each fraction, and mixed with 10 µl of 5X Laemmli buffer. Only 
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25 µl of the mix was then loaded onto SDS-PAGE (subsequent step described in 
chapter 4.6). To isolate RNA for the polysome fractions. 200 µl of each fraction was 
mixed with 800µl of TRIZOL reagent, and the resulting samples were treated as 
described in chapter 4.3. 
To create the curve presented in Figure 2.24A, the Absorbance of each one of 
the 44 fractions was measured at 254 nm on the Nanodrop2000 (Thermo scientific). 
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5 Appendix 
Figure 5.1: Histograms representing the binding location, in different genomic regions, obtained 
by FRACKING for SRSF7 and SRSF3, normalized by segment length. 
A) and B) Percentage of enrichment for the density of peaks (the number of peaks was divided by the 
length of each RNA feature). Bars represent relative peak abundance for: cytoplasm (Cyt), 
nucleoplasm (Npl) and chromatin (Chr) fractions, as stated in the legend.  
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Figure 5.2: RT-PCR for GAPDH, using mRNA from polysome fractionation. 
Presence and levels of GAPDH mRNA in the polysome fractions was tested by RT-PCR of mRNA 
samples extracted from the last five fractions of the polysome fractionation.  
 
 
Figure 5.3 Comparison between SRSF7 FRACKING data and standard-iCLIP data.  
Comparison of annotated transcripts with significant SRSF7 binding in a standard-iCLIP dataset 
(unpublished data, Müller-McNicoll et al.), and in the FRACKING dataset. The FRACKING data was 
obtained by combining the targets from cytoplasm, nucleoplasm and chromatin fractions. 
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Figure 5.4 Analysis of concordance between SRSF3 FRACKING data and standard-iCLIP 
datasets.  
A) Comparison of annotated transcripts with significant SRSF3 binding in two standard-iCLIP datasets 
one, in dark gray produced in 2015, unpublished (Müller-McNicoll et al.), and one published in 2010, 
light gray [24] B) Comparison of annotated transcripts with significant SRSF3 binding in a standard-
iCLIP dataset, light gray (Müller-McNicoll, et al.), and in the FRACKING dataset, dark gray. The data 
for FRACKING in this case was obtained by combining the targets from cytoplasm, nucleoplasm and 
chromatin fractions. C) Comparison of annotated transcripts with significant SRSF3 binding in a 
standard-iCLIP dataset, light gray [24], and FRACKING data, dark gray. 
 
 
 
Figure 5.5 SRSF7 binding to MALAT1 transcripts in different fractions after normalization for 
the total number of peaks detected in each fraction. 
SRSF7 binding to the MALAT1 transcript was normalized by dividing the binding signal of SRSF7 
along  MALAT1 by the whole number of binding detected in the specific dataset from the different 
fractions.   
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Figure 5.6 Correlation of SRSF7 FRACKING data for chromatin, nucleoplasm and cytoplasm.  
Significant tags were assigned to their respective transcripts and cross-correlated between each of the 
four A) SRSF7 chromatin replicates, B) SRSF7 nucleoplasmic replicates and C) SRSF7 cytoplasmic 
replicates. Pearson correlation was used for this analysis. For the values of correlation refer to Table 
5.4 for chromatin, Table 5.5 for nucleoplasm and 5.6 for cytoplasm. 
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Figure 5.7 Correlation of SRSF3 FRACKING data for chromatin, nucleoplasm and cytoplasm. 
Significant tags were assigned to their respective transcripts and cross-correlated between each of the 
eight, A) SRSF3 chromatin replicates, B) SRSF3 nucleoplasmic replicates and C) SRSF3 cytoplasmic 
replicates. The replicates with higher correlation values are shown in closer proximity to one 
another.  Pearson correlation was used for this analysis. For the values of correlation refer to Table 5.7 
for chromatin, Table 5.8 for nucleoplasm and 5.9 for cytoplasm. 
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Table 5.1: Top 50 protein coding transcripts bound by SRSF7, in the subcellular fractions. 
Transcripts are ordered for their FRACKING signal intensity. 
 
Chromatin Nucleoplasm Cytoplasm 
Gene Symbol Gene Symbol Gene Symbol 
Srsf7 Srsf7 Srsf7 
Prex2 Dhx57 mt-Co1 
Dhx57 Prdm2 Scd2 
2610528E23Rik Snrpn 2610528E23Rik 
Hexb Prex2 Canx 
Wdr43 Ankrd44 Hexb 
Prdm2 Taf15 Gja1 
Heg1 Heg1 Slc38a2 
Hspa8 Cdk8 Lars2 
Lars2 Srrm2 Hsp90b1 
Huwe1 Hnrnpa2b1 Snrpn 
Srrm2 Hnrnph1 Slc7a5 
Ccdc44 Sfpq Dhx57 
Thada Ash1l Slc2a3 
Zbtb20 Zfp207 Lamc1 
Efna5 Tsga14 Nufip2 
Ash1l Ogt Itga6 
Eif4a2 Nasp Fat1 
Odz2 Luc7l3 Soat1 
Snrpn Sltm Huwe1 
Ptprg Rbm39 Elovl6 
Ankrd44 Huwe1 Lrp2 
Zfp207 Ddx5 Sfpq 
Nop56 A630089N07Rik mt-Nd6 
Auts2 Canx Nfe2l1 
Luc7l3 Thada Akap12 
Rbm39 Mapkapk2 Hsp90ab1 
Samd4 Hnrnpu Nedd4 
Msi2 Slc38a2 Atp1b1 
Hnrnph1 Snrpb Fn1 
Srgap2 Luc7l2 Vcl 
Cct6a Nufip2 Slc6a6 
Hnrnpa2b1 Srsf18 Enpp3 
Tsga14 Eif4a2 Itgb1 
Top2a Scd2 Taf15 
Gphn Ddx17 mt-Nd5 
Sfpq Slc1a3 Tmem47 
Taf15 Ewsr1 Srrm2 
Brca1 Zc3h11a Ankrd44 
Adcy1 Tardbp mt-Nd4 
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Luc7l2 Peg3 Msi2 
Cd44 Brca1 Eef2 
Sltm Elovl6 Slc4a7 
Kcnj3 Fus Gnb2l1 
Ncl 2610528E23Rik Gphn 
Lhfp Comp Prex2 
Rpl4 Samd4 Slc16a1 
Wwp2 Spnb2 Sltm 
Magi1 Zbtb20 Gpc3 
Rpl7a Srsf1 Atp13a3 
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Table 5.2: Top 50 protein coding transcripts bound by SRSF3, in the subcellular fractions. 
Transcripts are ordered for their FRACKING signal intensity. 
 
Chromatin Nucleoplasm Cytoplasm 
Gene Symbol Gene Symbol Gene Symbol 
Prex2 Srsf3 mt-Co1 
Thada Srrm2 mt-Nd5 
Prdm2 Nufip2 mt-Nd2 
Huwe1 Prdm2 Gja1 
Heg1 Cdk8 2610528E23Rik 
Srsf3 Huwe1 mt-Nd1 
Kcnj3 Ankrd44 mt-Cytb 
Ash1l Scd2 Canx 
2610528E23Rik Heg1 Scd2 
Adam12 Snrpn mt-Nd4 
Pdzrn3 Gja1 Slc2a3 
Snrpn Phc1 Srsf3 
Tsga14 Qser1 Gnb2l1 
Ankrd44 Tsga14 Nufip2 
Strc mt-Nd1 Eef2 
Nufip2 Slc2a3 Wwp2 
Xkr6 Canx Hsp90ab1 
Adcy1 mt-Nd5 Lars2 
Hexb Ash1l Huwe1 
Srrm2 Prex2 Gphn 
Magi1 Slc38a2 Slc2a1 
Atg2b Fat1 Soat1 
Hnrnpa2b1 2810474O19Rik Slc38a2 
Zfp207 Kcnj3 Slc7a5 
Taf15 Ogt Hexb 
Phc1 Pkm2 Sltm 
Ext1 2610528E23Rik Hist1h4d 
Rbpms mt-Co1 Nedd4 
Zeb2 Zfp207 Itga6 
Pbx3 Gnb2l1 Ywhae 
Top2a Hsn2 Hsp90b1 
Shroom2 Hnrnpa2b1 mt-Nd6 
Msi2 Sema6a Eef1a1 
Sema6a Thada Pabpc1 
Efna5 mt-Cytb Npm1 
Lars2 Eef2 Tubb5 
Odz3 Taf15 Snrpn 
Jarid2 Hsp90ab1 Eif4g2 
Agbl1 Setd5 Srrm2 
Grip1 Pabpc1 Atp1b1 
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Mid1 Elovl6 Actb 
Dnmt3b Zbtb20 Fat1 
Gphn Fn1 Nptn 
Auts2 Ddx17 Zbtb20 
Hnrnph1 Adcy1 Msi2 
Lhfp Bat2l2 Atp2a2 
Mars Tcf20 Phc1 
Npm1 Npm1 Comp 
Ewsr1 Eif4g2 Gpc3 
Rbm39 Nedd4 Slc16a1 
 
 
 
 
 
Table 5.3: List of primers used in this study. 
 
Num Name Sequence 
1 SRSF7 Ex3 Fw CCTCGGAGATCTCGTTTTGA 
2 SRSF7 Ex5 Rv GGATCGGGAATGGGATCTA 
3 SRSF7 Ex4 Fw CGCCTTGCAAATCCGACAAT 
4 SRSF7 Intr4 Rv GTTTGCAGGTCGACCCTCTT 
5 SRSF3 Ex3 Fw TGATTACCGCAGGAGGAGTC 
6 SRSF3 Ex4 Rv TGACGCTGAAAGGGCTAGTT 
7 hnRNPh1 Ex3 Fw GCGAGGCTTTTGTTGAACTT 
8 hnRNPh1 Ex4 Rv TCAACACCCAATCCATTTCA 
9 Arglu1 Ex2 Fw GGAAAAGCAGTTGCTCGAAG 
10 Arglu1 Intr3 Rv TTCTGCTCCAGCTGCTGATA 
11 GAPDH F GCAGTGGCAAAGTGGAGATT 
12 GAPDH R CACCCCATTTGATGTTAGTGG 
 
 
 
 
Table 5.4 Pearson correlation scores of SRSF7 chromatin FRACKING replicates. 
  Rep 1 Chr Rep 2 Chr Rep 3 Chr Rep 4 Chr 
Rep 1 Chr 1 0.86 0.34 0.48 
Rep 2 Chr 0.86 1 0.49 0.45 
Rep 3 Chr 0.34 0.49 1 0.56 
Rep 4 Chr 0.48 0.45 0.56 1 
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Table 5.5 Pearson correlation scores of SRSF7 nucleoplasm FRACKING replicates. 
  Rep 1 Npl Rep 2 Npl Rep 3 Npl Rep 4 Npl 
Rep 1 Npl 1 0.73 0.91 0.05 
Rep 2 Npl 0.73 1 0.77 0.27 
Rep 3 Npl 0.91 0.77 1 0.05 
Rep 4 Npl 0.05 0.27 0.05 1 
 
 
 
Table 5.6 Pearson correlation scores of SRSF7 cytoplasm FRACKING replicates. 
  Rep 1 Cyt Rep 2 Cyt Rep 3 Cyt Rep 4 Cyt 
Rep 1 Cyt 1 0.91 0.76 0.81 
Rep 2 Cyt 0.91 1 0.7 0.74 
Rep 3 Cyt 0.76 0.7 1 0.57 
Rep 4 Cyt 0.81 0.74 0.57 1 
 
 
Table 5.7 Pearson correlation scores of SRSF3 chromatin FRACKING replicates. 
  
Rep  1 
Chr 
Rep 2 
Chr 
Rep 3 
Chr 
Rep 4 
Chr 
Rep 5 
Chr 
Rep 6 
Chr 
Rep 7 
Chr 
Rep 8 
Chr 
Rep  1 
Chr 1 0.39 0.76 0.74 0.49 0.22 0.3 0.27 
Rep 2 
Chr 0.39 1 0.44 0.45 0.43 0.53 0.55 0.57 
Rep 3 
Chr 0.76 0.44 1 0.93 0.8 0.26 0.44 0.35 
Rep 4 
Chr 0.74 0.45 0.93 1 0.8 0.31 0.48 0.4 
Rep 5 
Chr 0.49 0.43 0.8 0.8 1 0.41 0.69 0.6 
Rep 6 
Chr 0.22 0.53 0.26 0.31 0.41 1 0.89 0.9 
Rep 7 
Chr 0.3 0.55 0.44 0.48 0.69 0.89 1 0.98 
Rep 8 
Chr 0.27 0.57 0.35 0.4 0.6 0.9 0.98 1 
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Table 5.8 Pearson correlation scores of SRSF3 nucleoplasm FRACKING replicates. 
  
Rep 1 
Npl 
Rep 2 
Npl 
Rep 3 
Npl 
Rep 6 
Npl 
Rep 7 
Npl 
Rep 8 
Npl 
Rep 4 
Npl 
Rep 5 
Npl 
Rep 1 
Npl 1 0.5 0.66 0.59 0.56 0.55 0.56 0.24 
Rep 2 
Npl 0.5 1 0.68 0.62 0.65 0.7 0.43 0.62 
Rep 3 
Npl 0.66 0.68 1 0.73 0.7 0.75 0.65 0.59 
Rep 6 
Npl 0.59 0.62 0.73 1 0.96 0.9 0.49 0.38 
Rep 7 
Npl 0.56 0.65 0.7 0.96 1 0.95 0.4 0.39 
Rep 8 
Npl 0.55 0.7 0.75 0.9 0.95 1 0.4 0.48 
Rep 4 
Npl 0.56 0.43 0.65 0.49 0.4 0.4 1 0.35 
Rep 5 
Npl 0.24 0.62 0.59 0.38 0.39 0.48 0.35 1 
 
 
 
 
Table 5.9 Pearson correlation scores of SRSF3 cytoplasm FRACKING replicates. 
  
Rep 1 
Cyt 
Rep 2 
Cyt 
Rep 3 
Cyt 
Rep 4 
Cyt 
Rep 5 
Cyt 
Rep 6 
Cyt 
Rep 8 
Cyt 
Rep 7 
Cyt 
Rep 1 
Cyt 1 0.4 0.44 0.47 0.75 0.5 0.85 0.71 
Rep 2 
Cyt 0.4 1 0.94 0.92 0.65 0.83 0.56 0.29 
Rep 3 
Cyt 0.44 0.94 1 0.97 0.69 0.89 0.59 0.35 
Rep 4 
Cyt 0.47 0.92 0.97 1 0.75 0.93 0.61 0.37 
Rep 5 
Cyt 0.75 0.65 0.69 0.75 1 0.76 0.83 0.63 
Rep 6 
Cyt 0.5 0.83 0.89 0.93 0.76 1 0.62 0.43 
Rep 8 
Cyt 0.85 0.56 0.59 0.61 0.83 0.62 1 0.82 
Rep 7 
Cyt 0.71 0.29 0.35 0.37 0.63 0.43 0.82 1 
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Glossary 
 
40S 
	  
eukaryotic small ribosomal subunit 
60S 
	  
eukaryotic large ribosomal subunit 
80S  
	  
eukaryotic ribosome 
ARGLU1 
	  
arginine and glutamate-rich protein 1 
CBC 
	  
CAP binding complex 
CBP 
	  
CAP binding protein 
cDNA 
	  
complementary DNA 
Chr 
	  
chromatin 
CHX 
	  
cycloheximide 
CLIP 
	  
ultraviolet crosslinking immunoprecipitation 
Cyt 
	  
cytoplasm 
cyto-RT-PCR cytoplasmic RT-PCR 
ddH2O 
	  
double distilled water 
DECID 
	  
decay-inducing complex 
DNA 
	  
deoxyribonucleic acid 
EDTA 
	  
ethylenediaminetetraacetic acid 
EJC 
	  
exon junction complex 
ESE 
	  
exonic splicing enhancers 
Ex 
	  
exon 
FRACKING 
	  
fractionation-iCLIP 
GAPDH 
	  
glycerinaldehyd-3phosphat-Dehydrogenase 
GFP 
	  
green fluorescent protein 
GNB2L1 
	  
guanine nucleotide-binding protein subunit beta-2-like 
1 
HITS-CLIP 
	  
high-throughput CLIP sequencing 
hnRNP 
	  
heterogeneous nuclear  RNP 
HNRNPH1 
	  
heterogeneous nuclear RNP H1  
iCLIP 
	  
individual nucleotide resolution CLIP 
IgG 
	  
immunoglobin G 
IP 
	  
immunoprecipitation 
ISE 
	  
intronic splicing enhancers 
L 
	  
long 
lincRNA 
	  
long non coding RNA 
M 
	  
medium 
mAb104 
	  
mouse antibody 104 
MALAT1 
	  
metastasis associated lung adenocarcinoma transcript 1 
miRNA 
	  
microRNA 
mRNA 
	  
messanger RNA 
mt-ncRNA 
	  
mitochondrial non coding RNA 
ncRNA 
	  
non coding RNA 
NMD 
	  
nonsense-mediated decay 
NMTR 
	  
nonsense mediate translate repression 
NP-40 
	  
tergitol-type NP-40 
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NPC 
	  
nuclear pore complex 
Npl 
	  
nucleoplasm 
nt 
	  
nucleotides 
NXF1 
	  
nuclear export factor 1 
ORF 
	  
open reading frame 
P-TEFb 
	  
positive transcription elongation factor 
PAR-CLIP 
	  
photoactivatable ribonucleotide enhanced CLIP 
PCR 
	  
polymerase chain reaction 
Pol II 
	  
RNA Polymerase II 
Pre-mRNA 
	  
precursor mRNA 
PTC 
	  
premature stop codon 
RBP 
	  
RNA binding proteins 
RIP-Chip 
	  
RBP immunoprecipitation with microarray analysis 
RNA 
	  
ribonucleic acid 
RNA-seq 
	  
RNA sequencing 
RNP 
	  
ribonucleo-protein particles 
RRM 
	  
RNA recognition motif 
rRNA 
	  
ribosomal RNA 
S 
	  
short 
snoRNA 
	  
small nucleolar RNA 
snRNA 
	  
small nuclear RNA 
SR-protein 
	  
serine-arginine proteins 
SRSF 
	  
serine-arginine-rich splicing factor 
tRNA 
	  
transfer RNA 
U2AF 
	  
U2 auxiliary factor 
UPF 
	  
regulator of nonsense transcripts 
UTR 
	  
untranslated regions 
UV 
	  
ultraviolet 
WT 
	  
wildtype 
ZnF 
	  
zinc finger domain 
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